Chloroquine diphosphate

Name: Chloroquine diphosphate
Brand: Selleck Chemicals
SKU: S4157
Rating: 5 (157 reviews)

For research use only.

Catalog No.S4157

157 publications

Chloroquine diphosphate Chemical Structure

CAS No. 50-63-5

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).

Selleck's Chloroquine diphosphate has been cited by 157 publications

Gut, 2021, 70(5):890-899

PubMed: 32816920 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4794

PubMed: 34373456 ( click the link to review the publication )

Dev Cell, 2021, S1534-5807(21)00518-9

PubMed: 34214490 ( click the link to review the publication )

Theranostics, 2021, 11(2):700-714

PubMed: 33391500 ( click the link to review the publication )

Autophagy, 2021, 1-19

PubMed: 33866937 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):65

PubMed: 33431801 ( click the link to review the publication )

PLoS Genet, 2021, 17(3):e1009383

PubMed: 33657091 ( click the link to review the publication )

Cancer Discov, 2021, 11(2):362-383

PubMed: 33158842 ( click the link to review the publication )

Mol Oncol, 2021, 15(4):1203-1216

PubMed: 33638615 ( click the link to review the publication )

Virulence, 2021, 12(1):509-519

PubMed: 33509041 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(6):2960-2974

PubMed: 34249438 ( click the link to review the publication )

J Immunol, 2021, ji2001404

PubMed: 33963043 ( click the link to review the publication )

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Antiviral Res, 2021, 185:104996

PubMed: 33309540 ( click the link to review the publication )

Antiviral Res, 2021, 187:105015

PubMed: 33444702 ( click the link to review the publication )

Biochem Pharmacol, 2021, 186:114475

PubMed: 33609560 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00673-w

PubMed: 34017066 ( click the link to review the publication )

Front Pharmacol, 2021, 12:589273

PubMed: 34093169 ( click the link to review the publication )

Life Sci, 2021, 275:119355

PubMed: 33744326 ( click the link to review the publication )

Cell Biosci, 2021, 11(1):124

PubMed: 34229754 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7117

PubMed: 34038010 ( click the link to review the publication )

Eur J Pharmacol, 2021, 908:174346

PubMed: 34270985 ( click the link to review the publication )

Immunobiology, 2021, 226(5):152124

PubMed: 34333403 ( click the link to review the publication )

Anticancer Drugs, 2021, 32(6):664-673

PubMed: 33929997 ( click the link to review the publication )
Planta Med, 2021, 10.1055/a-1348-1634

PubMed: 33477173 ( click the link to review the publication )

J Transl Med, 2021, 19(1):62

PubMed: 33568202 ( click the link to review the publication )

Cancer Med, 2021, 10.1002/cam4.3739

PubMed: 33626233 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2020.1740529

PubMed: 32164484 ( click the link to review the publication )

Autophagy, 2020, 22:1-10

PubMed: 32286915 ( click the link to review the publication )

EMBO Rep, 2020, 6;21(5):e49232

PubMed: 32239622 ( click the link to review the publication )

Aging Cell, 2020, 19(6):e13163

PubMed: 32475059 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):427

PubMed: 32513919 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):712

PubMed: 32873786 ( click the link to review the publication )

Cell Death Dis, 2020, 21;11(2):141

PubMed: 32081881 ( click the link to review the publication )

Cell Death Dis, 2020, 7;11(5):337

PubMed: 32382017 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):103

PubMed: 32029706 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001295R

PubMed: 33103304 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001413R

PubMed: 32860638 ( click the link to review the publication )

Cell Chem Biol, 2020, 19 pii: S2451-9456(20)30078-7

PubMed: 32243810 ( click the link to review the publication )

J Mol Med (Berl), 2020, 10.1007/s00109-020-01971-2

PubMed: 32897390 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:2015920

PubMed: 32908624 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1232816

PubMed: 33062133 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:8345246

PubMed: 33123317 ( click the link to review the publication )

J Cell Physiol, 2020, 24

PubMed: 32329068 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15813

PubMed: 33150736 ( click the link to review the publication )

Neuropharmacology, 2020, 168:108028

PubMed: 32151646 ( click the link to review the publication )

Biochem Pharmacol, 2020, 12:114023

PubMed: 32413426 ( click the link to review the publication )

Sci Rep, 2020, 10(1):614

PubMed: 31953486 ( click the link to review the publication )
Front Med (Lausanne), 2020, 7:591736

PubMed: 33644083 ( click the link to review the publication )

Gene, 2020, 755:144889

PubMed: 32534056 ( click the link to review the publication )

Phytomedicine, 2020, 80:153394

PubMed: 33130472 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):42

PubMed: 32169072 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

J Cardiovasc Transl Res, 2020, 10.1007/s12265-020-10075-8

PubMed: 33025271 ( click the link to review the publication )

Exp Eye Res, 2020, S0014-4835(20)30624-2

PubMed: 33227296 ( click the link to review the publication )

Toxicol In Vitro, 2020, 27;66:104837

PubMed: 32229166 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:9235-9244

PubMed: 32982310 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2020, gmaa097

PubMed: 33085742 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):551-560

PubMed: 32537026 ( click the link to review the publication )

Anticancer Drugs, 2020, 31(6):601-608

PubMed: 32011366 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Viruses, 2020, 12(7):E756

PubMed: 32674313 ( click the link to review the publication )

Theranostics, 2020, 10(5):1981-1996

PubMed: 32104496 ( click the link to review the publication )

BMC Complement Med Ther, 2020, 20(1):194

PubMed: 32576183 ( click the link to review the publication )

bioRxiv, 2020, 2020.10.02.324228

PubMed: 33024968 ( click the link to review the publication )

Vet Microbiol, 2020, 250:108860

PubMed: 33045632 ( click the link to review the publication )

Virol Sin, 2020, 10.1007/s12250-020-00320-4

PubMed: 33237393 ( click the link to review the publication )

Commun Biol, 2020, 13;3(1):25

PubMed: 31932716 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(3):2084-2100

PubMed: 32017705 ( click the link to review the publication )
Antiviral Res, 2020, 183:104933

PubMed: 32949635 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):539

PubMed: 32681018 ( click the link to review the publication )

mBio, 2020, 11(4):e01833-20

PubMed: 32820005 ( click the link to review the publication )

Adv Ther (Weinh), 2020, 2000034

PubMed: 32838027 ( click the link to review the publication )

Sci Adv, 2019, 5(10):eaax7142

PubMed: 31681849 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Theranostics, 2019, 9(26):8392-8408

PubMed: 31754404 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0236-y

PubMed: 31076723 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32395

PubMed: 31081930 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 456:49-58

PubMed: 31004702 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 30886151 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(15):5769-5785

PubMed: 31409760 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):118

PubMed: 30987681 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2019, 169:266-272

PubMed: 30453174 ( click the link to review the publication )

Front Oncol, 2019, 9:436

PubMed: 31192135 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:179

PubMed: 31337986 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1460

PubMed: 31920653 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114781

PubMed: 31618659 ( click the link to review the publication )

Int J Oncol, 2019, 54(5):1625-1638

PubMed: 30896863 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):931-941

PubMed: 30899392 ( click the link to review the publication )
Oncol Rep, 2019, 41(5):2803-2817

PubMed: 30864717 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1270-1277

PubMed: 31113618 ( click the link to review the publication )

AMB Express, 2019, 9(1):108

PubMed: 31309361 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(11):1053-1060

PubMed: 31407376 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Molecules, 2019, 24(15)

PubMed: 31357480 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4295

PubMed: 30327467 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):215

PubMed: 30180906 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):702

PubMed: 29899555 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29568063 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):556

PubMed: 29748581 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10923

PubMed: 30026540 ( click the link to review the publication )

Aquat Toxicol, 2018, 199:46-54

PubMed: 29605586 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:887-897

PubMed: 29740218 ( click the link to review the publication )

Int J Oncol, 2018, 53(1):215-224

PubMed: 29693166 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):2200-2212

PubMed: 30106132 ( click the link to review the publication )

Toxicology, 2018, 406-407:114-122

PubMed: 30053495 ( click the link to review the publication )

Am J Transl Res, 2018, 10(4):1229-1236

PubMed: 29736216 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2206-2214

PubMed: 30066934 ( click the link to review the publication )

Drug Des Devel Ther, 2018, 12:2413-2421

PubMed: 30122899 ( click the link to review the publication )
Med Sci Monit, 2018, 24:2339-2349

PubMed: 29667627 ( click the link to review the publication )

Cancer Lett, 2018, 436:129-138

PubMed: 30118840 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):221

PubMed: 30200999 ( click the link to review the publication )

Front Immunol, 2018, 9:1245

PubMed: 29922290 ( click the link to review the publication )

Mol Immunol, 2018, 99:115-123

PubMed: 29763880 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27788

PubMed: 30320898 ( click the link to review the publication )

Platelets, 2018, 29(7):695-701

PubMed: 28984160 ( click the link to review the publication )

Arch Virol, 2018, 163(3):623-632

PubMed: 29177545 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12020-12034

PubMed: 29552290 ( click the link to review the publication )

Leukemia, 2017, 10.1038/leu.2016.325

PubMed: 27857131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):162

PubMed: 29145888 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3015

PubMed: 28837148 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Sci Rep, 2017, 7:42748

PubMed: 28209994 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:973-982

PubMed: 28292026 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:400

PubMed: 28932708 ( click the link to review the publication )

Int J Mol Med, 2017, 10.3892/ijmm.2017.3008

PubMed: 28560385 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2017, 90:39-47

PubMed: 29155283 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7603-7615

PubMed: 31966605 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):122

PubMed: 28882160 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 42(5):1812-1821

PubMed: 28750364 ( click the link to review the publication )

Biomed Res Int, 2017, 2017:7097580

PubMed: 28706950 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 486(2):492-498

PubMed: 28320515 ( click the link to review the publication )

Oncotarget, 2017, 8(42):71642-71656

PubMed: 29069735 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2527

PubMed: 28005078 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1086-98

PubMed: 27185187 ( click the link to review the publication )

J Mol Neurosci, 2016, 60(2):205-13

PubMed: 27498200 ( click the link to review the publication )

J Mol Neurosci, 2016, 58(4):401-10

PubMed: 26635026 ( click the link to review the publication )

Arch Biochem Biophys, 2016, 590:37-47

PubMed: 26562437 ( click the link to review the publication )

F1000Res, 2016, 5:150

PubMed: 27134728 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep23056.

PubMed: 26976322 ( click the link to review the publication )

Oncotarget, 2016, 7(41):66360-66385

PubMed: 27626179 ( click the link to review the publication )

J Gen Virol, 2015, 96(12):3484-3492

PubMed: 26459826 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26109433 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).

Targets

TLR3 ^[4]
()

TLR7 ^[4]
()

TLR8 ^[4]
()

TLR9 ^[4]
()

ATM ^[1]
(Cell-free assay)

In vitro

Chloroquine is a chemotherapeutic agent for the clinical treatment of malaria. Chloroquine is able to bind to DNA, and inhibit DNA replication and RNA synthesis which in turn results in cell death. The effect of Chloroquine may also be related to the formation of a toxic heme-Chloroquine complex. Chloroquine inhibits trophozoite hemoglobin degradation through increasing vacuolar pH and inhibiting the activity of vacuolar phospholipase, vacuolar proteases, and heme polymerase^[1]. Chloroquine possesses definite antirheumatic properties. Chloroquine has immuno-modulatory effects, suppressing the production/release of tumour necrosis factor and interleukin 6. Moreover, Chloroquine exerts direct antiviral effects, inhibiting pH-dependent steps of the replication of several viruses including members of the flaviviruses, retroviruses, and coronaviruses. Its best-studied effects are those against HIV replication^[2]. Chloroquine can accumulate inside the macrophage phagolysosome by ion trapping where it exerts potent antifungal activity against Histoplasma capsulatum and Cryptococcus neoformans by distinct mechanisms. Chloroquine inhibits growth of H. capsulatum by pH-dependent iron deprivation, whereas it is directly toxic to C. neoformans^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human K562 cells	NVy5bFlbS3m2b4TvfIlkyqCjc4PhfS=>			NHjYW3FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1\|MT64N{BvVQ>?	MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3M{i1OlcoRjF6NUO4OVY4RC:jPh?=
human KB cells	MXfDfZRwfG:6aXRCpIF{e2G7			NEHjS4dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{BjgSCvaXPyc5Bt[XSnIH3leIhw\CxiSVO1NF0xNjZizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDZ2MEWyOEc,OTR4NEC1NlQ9N2F-
human MDA-MB-468 cells	NYnLU2lbS3m2b4TvfIlkyqCjc4PhfS=>		NIXWZmk1QCCq	MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XliaX6gdJJme2WwY3Wgc4YhOy53IIXNJFQuMDJvY3jsc5JwNTFySD3wbIVvd3ijennuMVExNXmuKT3OMG4u\GmndHj5cIJ2fGGwLUGtZY1qdmViaInkdo9kcGyxcnnk[UwhT0l3ME2yMlgyKM7:TR?=	Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7NEWxPVcoRjF7OUS1NVk4RC:jPh?=
human MCF7 cells	NUnTc3R6S3m2b4TvfIlkyqCjc4PhfS=>		NGDydHA1QCCq	NF3KOJZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZkhcW5icILld4Vv[2Vib3[gNE41KHWPIEGtLFEuMDRvKEetdIhmdnmuLUHIMYlucWSjen;bOEw2NWefcYXpco95[Wyrbj22MZltMWKnbor5cElxcXCncnnkbY4uPC27bDmtNWgu[mWwen;b[H1qdWmmYYrvcE0zMDOKKT3vcoUtKEeLNUC9OU42OSEQvF2=	NVHGcpl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OFUyQTdpPkG5PVQ2OTl5PD;hQi=>
human MDA-MB-231 cells	NXezcI9SS3m2b4TvfIlkyqCjc4PhfS=>		MXW0PEBp	NGWxUmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMz61JJVOKDRvKEKtZ4htd3KxLUGwTE1xcGWwb4jhfolvNTFyLYnsLU1PNE5vZHnleIh6dGK3dHHuMVEu[W2rbnWgbJllem:laHzvdoll\SxiR1m1NF03NjB6IN88US=>	NVfVcmVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OFUyQTdpPkG5PVQ2OTl5PD;hQi=>
human HeLa cells	NUT1S5pVS3m2b4TvfIlkyqCjc4PhfS=>			NWizenJKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBOXFRiYYPzZZktKEmFNUC9N\|Ah\|ryP	NUDLVIszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVQ{OjJpPkK0N\|U1OzJ{PD;hQi=>
human HepG2 cells	MXHDfZRwfG:6aXRCpIF{e2G7		M4LpdlQ5KGh?	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUO3MlY5KM7:TR?=	NWPyRlZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVUyQDZpPkKzPFE2OTh4PD;hQi=>
mammary tumor FM3A	M1TQVWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MUPDfZRwfG:6aXPpeJkhd2ZiY3;tdI92dmRid3HzJJRme3SnZDDh[4FqdnO2IH3veZNmKG2jbX3hdpkhfHWvb4KgSm0{SSClZXzsd{whTUN3MDC9JFAvODByMECwN{DPxE1w	NVPFUWllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK1O\|A{QDVpPkGyOVcxOzh3PD;hQi=>
red blood cells	M1HqfmFvfGmybHHzcY9lcWGuIHHzd4F6		MUW0PEBpenN?	M4n5W2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGZkSjFxQ3;seY1jcWFiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IIDhdoF{cXSnIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCdM1jdMYh6eG:6YX70bIlv\SCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wNFAyOSEQvF2u	M2jBRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O\|cxLz5{NU[1PVc4ODxxYU6=
red blood cells	M37kVWFvfGmybHHzcY9lcWGuIHHzd4F6		Mn;jOFghcHK\|	NGTj[nlCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lJIFv\CCyeYLpcYV1cGGvaX7lMZJme2m\|dHHueEBzcW6pIIP0ZYdmKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDWNU9UKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNuIFnDOVAhRSByLkCwOVUh\|ryPLh?=	NV;jdG5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNFc6OzdpPkKxNlA4QTN5PD;hQi=>
red blood cells	MYLBcpRqdWGuYYLpZYwh[XO\|YYm=			MnviRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCxdnHs[UBzcW6pIIP0ZYdmKGmwZnXjeIVlKGmwIILl[EBjdG:xZDDj[YxteyCrbjDwdoV{\W6lZTDv[kBCSitiaIXtZY4he2W{dX2gZpkh\HK3ZzDzeZNk\XC2aXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODB5ODFOwG0v	M2D3e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUO3O\|c6Lz5{MEmzO\|c4QTxxYU6=
red blood cells	M1nkfGFvfGmvYXzhdolidCCjc4PhfS=>		MYq0PEBpenN?	NUjPd\|ZiSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJIVzgXSqcn;jfZRq[yC\|dHHn[UBw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gUmY2PCCrbn\lZ5Rm\CCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KFt\|SG2tbJlxd3ijboTobY5mKGmwY3;ydI9z[XSrb36gZZN{[XluIFnDOVAhRSByLkCwPVQh\|ryPLh?=	M3[yT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nki1OVY6Lz5{M{[4OVU3QTxxYU6=
red blood cells	MofpRY51cW2jbHHybYFtKGG\|c3H5		M{KxfVQ5KGi{cx?=	NHzFdItCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKER4IHnu[oVkfGWmIHnuJIh2dWGwIF:gdI9{cXSrdnWgdoVlKGKub3;kJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{PIYU1pgXCxeHHueIhqdmVidYD0ZYtmKGGodHXyJFQ5KGi{czygTWM2OCB;IECuNFEh\|ryPLh?=	NF;QOHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
red blood cells	NHzD[pZCdnSrbXHsZZJq[WxiYYPzZZk>			NWjjXHZtSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGNjDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3hcJN1[XRicnXh[4VvfCCkYYPl[EBNTEhiYYPzZZktKEmFNUCgQUAxNjBzMTFOwG0v	M1jSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkKyN\|E4Lz5{OEKyNlMyPzxxYU6=
red blood cells	M3fvXmFvfGmvYXzhdolidCCjc4PhfS=>		NXXSZo1ZPzJiaILz	NHPGfYlCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKDOGNzDpcoZm[3SnZDDpckBpfW2jbjD0fZBmKEFvcH;zbZRqfmVicnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSC\|cHXjeJJweGixdH;t[ZRzcWOjbHz5MEBKSzVyIE2gNE4xOTJizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzMUW2Nkc,OjV\|MUG1OlI9N2F-
red blood cells	MmrTRY51cW2jbHHybYFtKGG\|c3H5			MVXBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG\|bX;kbZVuKG2jbHHybYFmKHKrbnegd5Ri\2ViaX7m[YN1\WRiaX6gdoVlKGKub3;kJINmdGy\|IHnuJJBz\XOnbnPlJI9nKEGEKzDoeY1idiC\|ZYL1cUBjgSCmcoXnJJN2e2OncITpZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yMUSg{txONg>?	NXPISlVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5N\|c4PzlpPkKwPVM4Pzd7PD;hQi=>
red blood cells	MnW2RY51cXCuYYPtc4Rq[WxiYYPzZZk>		NHXjTpI1QCCqcoO=	M3HvR2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lMEBu\W[ub4H1bY5mNXKnc3nzeIFvfCC{aX7nJJN1[WenIGDsZZNud2SrdX2g[oFt[2myYYL1cUBFPiCrbn\lZ5Rm\CCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[W[2ZYKgOFghcHK\|LDDJR\|UxKD1iMD6wNVQzKM7:TT6=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJyN{mzO{c,OjF{MEe5N\|c9N2F-
red blood cells	NUT3SmVKSW62aYDsZZNud2SrYXygZZN{[Xl?		Mme1O\|IhcHK\|	MYPBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hTDFyIHnu[oVkfGWmIHnuJIh2dWGwIILl[EBjdG:xZDDj[YxteyCjZoTldkA4OiCqcoOgZpkheGG{YYPpeIUhdGGldHH0[UBl\Wi7ZILv[4Vv[XOnIHHzd4F6NCCLQ{WwJF0hOC5yMUSzJO69VS5?	NFKySoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmxO\|g2Pyd-MkK5NVc5PTd:L3G+
red blood cells	NHvFNINCdnSrcHzhd41w\GmjbDDhd5NigQ>?		NHz5TJY1QCCqcoO=	M3P4XGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiYYPlfJVidCCncon0bJJw[3m2ZTDzeIFo\SCxZjDjbIxwem:zdXnu[U1{\W6\|aYTpeoUhWGyjc33v[Il2dSCoYXzjbZBienWvIF7GOVQhcW6oZXP0[YQhcW5iaIXtZY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDsZYN1[XSnIHTlbJllem:pZX7hd4Uh[XO\|YYmsJGlEPTBiPTCwMlAyPiEQvF2u	M3vCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkm2Olg{Lz5\|MEK5OlY5OzxxYU6=
red blood cells	NE\LeGJCdnSrbXHsZZJq[WxiYYPzZZk>		MUS5OkBpenN?	M4jjbGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCnYYLsfUB1em:yaH;6c4l1\SC\|dHHn[UBw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gSFYhcW5iaIXtZY4hemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KFt\|SG3ofZBwgGGwdHjpcoUhfXC2YXvlJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEG3JO69VS5?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2OEK4NUc,OjN2NEiyPFE9N2F-
FM3A	NFrVdWFHfW6ldHnvckBie3OjeR?=			MXjT[Yxm[3Srdnn0fUBnd3JiRl2zRUBk\WyuczDveoVzKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDhd{Bu\WGwIFXDOVAhemG2aX:sJGlEPTBiPTCwMlAyQSEQvF2u	M4Tj[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEC4O\|A5Lz5zMkSwPFcxQDxxYU6=
red blood cells	NYfkTnlVSW62aX3hcIFzcWGuIHHzd4F6		M37uVlQ5KGi{cx?=	MnXDRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvc3Xud4l1cX[nIGDsZZNud2SrdX2g[oFt[2myYYL1cUA{TDdiaX7m[YN1\WRiaX6gbJVu[W5iTzDwc5NqfGm4ZTDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdM1jdMYh6eG:6YX70bIlv\SC3cIThb4Uh[W[2ZYKgOFghcHK\|LDDJR\|UxKD1iMD6wNkDPxE1w	MmrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW1PVMoRjJzMUW1OVk{RC:jPh?=
red blood cells	M{jtW2FvfGmvYXzhdolidCCjc4PhfS=>		MYK3NkBpenN?	MYjBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2\|ZX7zbZRqfmViUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGQyOCCrbn\lZ5Rm\CCrbjDoeY1idiC2eYDlJGEueG:\|aYTpeoUhemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUB{eGWldILvdIhwfG:vZYTybYNidGy7LDDJR\|UxKD1iMD6wNkDPxE1w	M4DyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GxOVYzLz5{NUOxNVU3OjxxYU6=
red blood cells	NYfnNnl5SW62aX3hcIFzcWGuIHHzd4F6			MmDkRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhemmwZzDzeIFo\SCSbHHzcY9lcXWvIH\hcINqeGG{dX2gN2Q4KGmwZnXjeIVlKHerdHigbJVu[W5icnXkJIJtd2:mIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JHN[SlJiR4Ll[Y4hdWW2aH;kMEBKSzVyIE2gNE4xOjNizszNMi=>	Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkW2NFgoRjJ3N{K1OlA5RC:jPh?=
red blood cells	NF\5U25CdnSrbXHsZZJq[WxiYYPzZZk>			M1TmVGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1ib4\hcIUhfHKxcHjvfo9qfGVic4Th[4UhcW6oZXP0[YQhcW5icnXkJIJtd2:mIHPlcIx{KGmwIIDy[ZNmdmOnIH;mJGFDMyCqdX3hckB{\XK3bTDifUBlenWpIIP1d4NmeHSrYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xOjN{IN88UU4>	MmXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{e3O\|koRjJyOUO3O\|c6RC:jPh?=
red blood cells	MnzkRY51cW2jbHHybYFtKGG\|c3H5			NXPyUoszSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJFNFPyCDIHnu[oVkfGWmIHnuJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuzTH1pgXCxeHHueIhqdmViaX7jc5Jxd3KjdHnvckBi\nSncjCyOEBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEK0JO69VS5?	NXf3OYxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjFpPkK0PVAxOjZzPD;hQi=>
red blood cells	MluzRY51cW2jbHHybYFtKGG\|c3H5		NYDqV2hoPDhiaILz	NHnNclZCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKE6rZ3XybYFvKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNiYomgX\|NJZS2qeYDvfIFvfGirbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvODJ3IN88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyMES1PEc,Ojh6MEC0OVg9N2F-
red blood cells	MYLBcpRqeGyjc33v[IlidCCjc4PhfS=>		NHHHdY41QCCqcoO=	NI\COHJCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iM1S3JIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icHHyZZNqfGViZ4Lve5RpKGGodHXyJFQ5KGi{czDifUBJd2WlaIP0JFM{OzR{IIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODJ4IN88UU4>	NITKcXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEG5PVcxPid-M{CxPVk4ODZ:L3G+
HCT-8	M{fWcmFvfGmvaXPyc4Jq[WxiYYPzZZk>		MWe0PEBpenN?	MVnBcpRqdWmlcn;ibYFtKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDpcoZm[3SnZDDpckBpfW2jbjDIR3QuQCClZXzsd{Bi\nSncjC0PEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCyO{DPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7MUK4NEc,OTh3OUGyPFA9N2F-
red blood cells	M2XpZmFvfGmvYXzhdolidCCjc4PhfS=>		NWXlZ\|VtPzJiaILz	MkTBRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvc3Xud4l1cX[nIGDsZZNud2SrdX2g[oFt[2myYYL1cUBFOTBiaX7m[YN1\WRiaX6gbJVu[W5idInw[UBCNXCxc3n0bZZmKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCyYYLhd4l1\SCuYXP0ZZRmKGSnaInkdo9o\W6jc3WgZYN1cX[rdImgZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrczygTWM2OCB;IECuNFI6KM7:TT6=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB3NECzPEc,OjJyNUSwN\|g9N2F-
red blood cells	NVXTWpVnSW62aX3hcIFzcWGuIHHzd4F6		NV;SOXlrPzJiaILz	NWC4W5JzSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtd4Vve2m2aY\lJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGMUCgbY5n\WO2ZXSgbY4hcHWvYX6gRU1xd3OrdHn2[UBz\WRiYnzvc4Qh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHzhZ5RifGViZHXofYRzd2enbnHz[UBie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	M3rzNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKzNFc1Lz5{MUGyN\|A4PDxxYU6=
red blood cells	NFj1[GpCdnSrbXHsZZJq[WxiYYPzZZk>			M3HMWmFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hO0R5IHnu[oVkfGWmIHnuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB5MjDodpMh[nliU2nCVkBoemWnbjCxJJN1[WmwaX7nJIJie2WmIH\seY9zd22ndILpZ{Bie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OUK4N\|EoRjJ5NkmyPFMyRC:jPh?=
3D7	M{e3fGFvfGmybHHzcY9lcWGuIHHzd4F6			NEjGOINCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IGDsZZNud2SrdX2g[oFt[2myYYL1cUA{TDdicnnu[{B{fGGpZTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gdIFz[XOrdHXtbYEh[nliTXHsd5RifCCjc4PhfUwhUUN3MDC9JFAvODNizszNMi=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3OEOwNEc,OjJ6NUizNFA9N2F-
red blood cells	M1zTUWFvfGmvYXzhdolidCCjc4PhfS=>			Mm\iRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCoYXzjbZBienWvIEPEO2EhcW6oZXP0[YQhcW5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheGG{YYPpeIUh\3Kxd4ToJIFnfGW{IEK0JIhzeyCkeTDbN2hecHmyb4jhcpRpcW6nIHnuZ49zeG:{YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlA{PiEQvF2u	Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7ME[yNFAoRjJ3OUC2NlAxRC:jPh?=
red blood cells	MYXBcpRqdWGuYYLpZYwh[XO\|YYm=			M17VNGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYPlcpNqfGm4ZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hTDZiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBx[XKjc3n0bYMhVESKIHHjeIl3cXS7IHL5JG1idHO2YYSgdoVi\2WwdDDiZZNm\CC\|cHXjeJJweGixdH;t[ZRzcWNibXX0bI9lNCCLQ{WwJF0hOC5yNDFOwG0v	NHrVT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwNFQ2QCd-Mki4NFA1PTh:L3G+
red blood cells	NIfxTJZCdnSrcHzhd41w\GmjbDDhd5NigQ>?			NHy3OJdCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iRE[gbY5n\WO2ZXSgbY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNZYx{fGG2IILlZYdmdnRiYnHz[YQhVESKIHHzd4F6NCCLQ{WwJF0hOC5yNDFOwG0v	M3\pbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk5Lz5{OEOxOVU6QDxxYU6=
red blood cells	MV\BcpRqeGyjc33v[IlidCCjc4PhfS=>			NEC5c\|VCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iRE[gbY5n\WO2ZXSgbY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDwZZJie2m2aXOgUGRJKGG\|c3H5MEBKSzVyIE2gNE4xPCEQvF2u	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEWwPUc,OjR7MEC1NFk9N2F-
Vero	NYrwUnd4SW62aX3hcIFzcWGuIHHzd4F6		M3jU[FczKGi{cx?=	NITWeVRCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3z[Y5{cXSrdnWgVIxie22xZHn1cUBn[WylaYDhdpVuKER4IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KCiFZYLjc5BqfGinY4XzJIFmfGirb4DzLUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IIDhdoF{cXSnIFzETEBi[3Srdnn0fUBi\nSncjC3NkBpenNuIFnDOVAhRSByLkC1JO69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh\|M{WyNEc,OTl6M{O1NlA9N2F-
red blood cells	NH\aPFFCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MVu0JIhzew>?	MnHZRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY4hcHWvYX6gdoVlKGKub3;kJINmdGy\|IHHmeIVzKDRiaILzMEBKSzVyIE2gNE4xPTVizszNMi=>	MljPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7OUC4OlUoRjF5OUmwPFY2RC:jPh?=
red blood cells	NVjUV5V1SW62aYDsZZNud2SrYXygZZN{[Xl?		NHzJeVg1QCCqcoO=	NFnyWpJCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZNmdnOrdHn2[UBzcW6pIIP0ZYdmKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTCzSFchcW6oZXP0[YQhcW5iaIXtZY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IES4JIhzeyxiSVO1NEA:KDBwMEi5JO69VS5?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJyN{mzO{c,OjF{MEe5N\|c9N2F-
B-cells	NXjhVnhJTnWwY4Tpc44h[XO\|YYm=			NGK5[5ZEd26lZX70doF1cW:wIILldZVqemWmIH\vdkBp[WyoLX3hfIlu[WxiaX7obYJqfGmxbjDv[kBEeEdvT1TOJIVn\mWldDDvckB1cHmvaXTpcoUhfXC2YXvlJIJ6KFeHSFmgNlMyKG23cnnu[UBDNWOnbHzzJIlvKHSqZTDwdoV{\W6lZTDv[kBidHCqYT3zTYdONixiRVO1NEA:KDBwMUGg{txONg>?	NIHjTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMESwOlY1QCd-MUC0NFY3PDh:L3G+
red blood cells	NWPQZm5QSW62aYDsZZNud2SrYXygZZN{[Xl?		NFT1NJc1QCCqcoO=	NXT0U4x3SW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[UBidmRicInybY1mfGijbXnu[UBz\XOrc4ThcpQhWGyjc33v[Il2dSCoYXzjbZBienWvIFuxJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icHHyZZNqfGVidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCdM1jdMYh6eG:6YX70bIlv\SCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	NYThN41CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFY5OTZpPkK1O\|Q3QDF4PD;hQi=>
red blood cells	NEnrS21CdnSrcHzhd41w\GmjbDDhd5NigQ>?		NWX6VoM2PDhiaILz	M2DTPGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWvdJlzcW2ndHjhcYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGsyKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCdM1jdMYh6eG:6YX70bIlv\SCrbnPvdpBwemG2aX;uJIlv[3WkYYTl[EBnd3JiNEigbJJ{KHC{aX;yJJRwKFt\|SG2tbJlxd3ijboTobY5mKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBtcSxiSVO1NEA:KDBwMUK1JO69VS5?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4OEW0N{c,OjR{Nki1OFM9N2F-
red blood cells	M{DyR2FvfGmvYXzhdolidCCjc4PhfS=>			NWq2d5pCSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDtZYxiemmjZTD0do9xcG:8b3n0[UB{fGGpZTDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiQVKrJIh2dWGwIIPldpVuKGK7IHTyeYche3W\|Y3XweIljcWyrdImgZZN{[XluIFnDOVAhRSByLkGyO\|kh\|ryPLh?=	MnrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{e3O\|koRjJyOUO3O\|c6RC:jPh?=
red blood cells	NVHKUVBTSW62aX3hcIFzcWGuIHHzd4F6		NUDCVYdxPDhiaILz	MXzBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGZkSjFiaX7m[YN1\WRiaX6gbJVu[W5icnXkJIJtd2:mIHPlcIx{KGGodHXyJFQ5KGi{czDifUBcO0ifLXj5dI95[W62aHnu[UBqdmOxcoDvdoF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5zM{Kg{txONg>?	NXPv[XdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4NFA1PThpPkK4PFAxPDV6PD;hQi=>
red blood cells	NYfnSHBQSW62aYDsZZNud2SrYXygZZN{[Xl?		NIfETW41QCCqcoO=	M4DjNGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JJJqdmdic4Th[4UhWGyjc33v[Il2dSCoYXzjbZBienWvIGeyJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMtKEmFNUCgQUAxNjF\|ODFOwG0v	NH;sOWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKwO\|k{Pyd-MkGyNFc6Ozd:L3G+
red blood cells	NEPXbW5CdnSrcHzhd41w\GmjbDDhd5NigQ>?		NFXzVXk1QCCqcoO=	MmjBRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKFd{IHnu[oVkfGWmIHnuJIh2dWGwIILl[EBjdG:xZDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKrbnetd5Ri\2VicHHyZZNqfGViZ4Lve5RpKGGodHXyJFQ5KGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IECuNVQh\|ryPLh?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ7NUi4O{c,OjF{OUW4PFc9N2F-
RPMI1640	Ml;0RY51cXCjcnHzbZRq[yCjc4PhfS=>		NV\FOG5rPzJiaILz	M4D4eGFvfGmyYYLhd4l1cWNiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSg[ZJ6fGi{b3P5eIlkKHO2YXflJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDLNUBqdm[nY4Tl[EBqdiCqdX3hckBTWE2LMU[0NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTlLUJJN1[WmwaX7nJIJie2WmIIPw[YN1em:\|Y3;wbYMh[W6jbInzbZMtKEmFNUCgQUAxNjF2IN88UU4>	M1\icFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUKyNlI3Lz5{NkmyNlIzPjxxYU6=
red blood cells	NF33cZNCdnSrcHzhd41w\GmjbDDhd5NigQ>?		NWL6VFE3PDhiaILz	M2jWeGFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWvdJlzcW2ndHjhcYlv\SC{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGsyKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNiYomgX\|NJZWi7cH;4ZY51cGmwZTDpcoNwenCxcnH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4yPSEQvF2u	Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NESyNVUoRjJ5M{S0NlE2RC:jPh?=
red blood cells	M1rsTmFvfGmybHHzcY9lcWGuIHHzd4F6		NEfWVWo1QCCqcoO=	NYXONopWSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDhd4V5fWGuIHXyfZRpem:leYTlJJN1[WenIH;mJINpdG:{b4H1bY5mNXKnc3nzeIFvfCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gSIQzKGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bi\nSncjC0PEBpenNiYomgcIFkfGG2ZTDk[Yh6\HKxZ3XuZZNmKGG\|c3H5MEBKSzVyIE2gNE4yPSEQvF2u	NXW4[m8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVY3QDNpPkOwNlk3Pjh\|PD;hQi=>
red blood cells	MWnBcpRqdWGuYYLpZYwh[XO\|YYm=		NVTLeJNHPDhiaILz	MmPSRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhdXWudHnkdpVoNXKnc3nzeIFvfCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gT\|EhcW6oZXP0[YQhcW5iaIXtZY4hemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KDOKLXj5dI95[W62aHnu[UBqdmOxcoDvdoF1cW:wIHHmeIVzKDR6IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNVch\|ryPLh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ2NEW0NUc,OjF4NES1OFE9N2F-
L6	NHrZPYZCdnSrcHHyZZNqfGmlIHHzd4F6		NX;6b4lGPDhiaILz	M2[yVmFvfGmyYYLhd4l1cWNiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gT\|EhcW6oZXP0[YQhcW5icnH0JGw3KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gdIFz[XOrdHWg[5Jwf3SqIIDy[Ylv[3WkYYTl[EBnd3JiNEigbJJ{KGKnZn;y[UBcO0ifaInwc5hidnSqaX7lJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDbN2hecHmyb4jhcpRpcW6nIHnuZ49zeG:{YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlE4QCEQvF2u	M1PG[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUO3NlI5Lz5{MUmzO\|IzQDxxYU6=
L6	NV3mb41IS3m2b4TvfIlkcXS7IHHzd4F6			MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBz[XRiTE[gZ4VtdHNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlE5QDVizszNMi=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEG3O{c,OTdzN{ixO\|c9N2F-
red blood cells	NEjzbnZCdnSrcHzhd41w\GmjbDDhd5NigQ>?		MoTrOFghcHK\|	M3\oe2FvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RidHjlJI12dHSrZIL1[{1z\XOrc4ThcpQhWGyjc33v[Il2dSCoYXzjbZBienWvIF\SR{0{KGmwZnXjeIVlKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gdIFz[XOrdHWg[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCKb3XjbJN1KDN\|M{SyJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMkC3JO69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF7OUewOkc,OzBzOUm3NFY9N2F-
red blood cells	Mkm2RY51cW2jbHHybYFtKGG\|c3H5		Mlz6OFghcHK\|	NEj4OWFCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSg[ZJ6fGi{b3P5eIlkKHO2YXflJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDLNUBqdm[nY4Tl[EBqdiCqdX3hckBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK\|IHL5JHs{UF1vaInwc5hidnSqaX7lJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUCgQUAxNjJzIN88UU4>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6NUW2PUc,OjN4OEW1Olk9N2F-
red blood cells	MX7BcpRqeGyjc33v[IlidCCjc4PhfS=>		NUPI[JNSPDhiaILz	MkntRY51cXCuYYPtc4Rq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT2gZY5lKHC7cnnt[ZRp[W2rbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCNMTDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgX\|NJZWi7cH;4ZY51cGmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFQ5KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMkKg{txONg>?	NEPYfVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSzPFU5Pid-MkG0N\|g2QDZ:L3G+
red blood cells	MY\BcpRqdWGuYYLpZYwh[XO\|YYm=			NXHTU4FUSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3Ricnnu[{B{fGGpZTDQcIF{dW:maYXtJIZidGOrcHHyeY0hXzJiaX7m[YN1\WRid3n0bEBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkh\myxdzDjfZRwdWW2comsJGlEPTBiPTCwMlIzQSEQvF2u	MorSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkW2NFgoRjJ3N{K1OlA5RC:jPh?=
L6	MWXBcpRqeGG{YYPpeIlkKGG\|c3H5			MUfBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVuIID5dolu\XSqYX3pcoUuemW\|aYP0ZY51KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDLNUBmenm2aILvZ5l1\SC\|dHHn[UBqdm[nY4Tl[EBz[XRiTE[gZ4VtdHNuIFnDOVAhRSByLkKzJO69VS5?	M37nc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUS5NFY5Lz5zN{m0PVA3QDxxYU6=
L6	NUm3O4I2SW62aYDsZZNud2SrYXygZZN{[Xl?			MXzBcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nIHHu[EBxgXKrbXX0bIFucW6nLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hUzFiaX7m[YN1\WRiaX6gdoF1KEx4IHPlcIx{NCCLQ{WwJF0hOC5{NTFOwG0v	NGnhZVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm0NlQ{QSd-MUm5OFI1Ozl:L3G+
red blood cells	NFfubY5CdnSrbXHsZZJq[WxiYYPzZZk>		NG\DXlU4OiCqcoO=	MkLERY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBYOiCrbn\lZ5Rm\CCrbjDoeY1idiCDLYDvd4l1cX[nIILl[EBjdG:xZDDj[YxteyCjZoTldkA4OiCqcoOgZpkhdGGldHH0[UBl\Wi7ZILv[4Vv[XOnIHHzd4F6NCCLQ{WwJF0hOC5{NTFOwG0v	M1fGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKzNFc1Lz5{MUGyN\|A4PDxxYU6=
red blood cells	M{D4WGFvfGmvYXzhdolidCCjc4PhfS=>		M3nMelQ5KGi{cx?=	NFy5eYhCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCClaHzvdo9yfWmwZT3y[ZNqe3SjboSgVIxie22xZHn1cUBn[WylaYDhdpVuKE[lTUK5JIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMh[nliW{PIYU1pgXCxeHHueIhqdmViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNlYh\|ryPLh?=	M3\VcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OECwOFU5Lz5{OEiwNFQ2QDxxYU6=
red blood cells	NECycllCdnSrbXHsZZJq[WxiYYPzZZk>		NV\PcmozPDhiaILz	NX25OFg5SW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RibYXseIllenWpLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hXE17MD3DNmIhcW6oZXP0[YQhcW5iaIXtZY4hVyCyb4PpeIl3\SC{ZXSgZoxwd2RiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcO0ifLXj5dI95[W62aHnu[UB2eHSja3WgZYZ1\XJiNEigbJJ{NCCLQ{WwJF0hOC5{ODFOwG0v	NHzDSnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
red blood cells	MlvMRY51cW2jbHHybYFtKGG\|c3H5		NFX6bmE1QCCqcoO=	M4fMVGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KHKrbnegd5Ri\2ViUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGRlOiCrbn\lZ5Rm\CC5aYToJIh2dWGwIILl[EBjdG:xZDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBUYUKUIFfy[YVvKG2ndHjv[EwhUUN3MDC9JFAvOjh3IN88UU4>	NUXHdmV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlU3ODhpPkK1O\|I2PjB6PD;hQi=>
red blood cells	MmC2RY51cW2jbHHybYFtKGG\|c3H5		NWX1ToRQQTZiaILz	MYXBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\SCjbnSgdJlzcW2ndHjhcYlv\S2{ZYPpd5RidnRiZXHycJkhfHKxcHjvfo9qfGVic4Th[4Uhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwIHj1cYFvKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCdM1jdbJlxd3ijboTobY5mKHWydHHr[UBi\nSncjC5OkBpenNuIFnDOVAhRSByLkK5JO69VS5?	NITDU4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI5OSd-MkO0OFgzQDF:L3G+
red blood cells	NVOyUppJSW62aX3hcIFzcWGuIHHzd4F6		MkK4O\|IhcHK\|	MkXRRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5Qh[2iub4LvdZVqdmVvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBYOiCrbn\lZ5Rm\CCrbjDoeY1idiC2eYDlJGEueG:\|aYTpeoUhemWmIHLsc49lKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUB{eGWldILvdIhwfG:vZYTybYNidGy7LDDJR\|UxKD1iMD6zNVYh\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNzMUW2Nkc,OjV\|MUG1OlI9N2F-
red blood cells	NITFVG9CdnSrbXHsZZJq[WxiYYPzZZk>		NHPt[WY4OiCqcoO=	MVPBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIILl[EBjdG:xZDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVWGuc4TheEBz\WGpZX70JIJie2WmIFzETEBie3OjeTygTWM2OCB;IECuN\|E4KM7:TT6=	M1fnWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkKyN\|E4Lz5{OEKyNlMyPzxxYU6=
red blood cells	NUn4SWl7SW62aYDsZZNud2SrYXygZZN{[Xl?		M3vabFczKGi{cx?=	NVr3S45ySW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U1z\XOrc4ThcpQhWGyjc33v[Il2dSCoYXzjbZBienWvIGeyJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB5MjDodpMh[nlicHHyZZNqfGVibHHjeIF1\SCmZXj5[JJw\2WwYYPlJIF{e2G7LDDJR\|UxKD1iMD6zNVcyKM7:TT6=	NVX6[ppsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NVc5PTdpPkKyPVE4QDV5PD;hQi=>
red blood cells	MWjBcpRqeGyjc33v[IlidCCjc4PhfS=>		Mki5O\|IhcHK\|	NHP3S5FCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTDh[4FqdnO2IHPocI9zd3G3aX7lMZJme2m\|dHHueEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iV{KgbY5n\WO2ZXSgbY4hemWmIHLsc49lKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDwZZJie2m2aXOgUGRJKGG\|c3H5MEBKSzVyIE2gNE4{QSEQvF2u	M4PqXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOVA6Lz5{NEmwNFUxQTxxYU6=
red blood cells	M2T0V2FvfGmvYXzhdolidCCjc4PhfS=>		MmWxOFghcHK\|	MUHBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\SCjbnSgdJlzcW2ndHjhcYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGsyKGmwZnXjeIVlKGmwIHj1cYFvKE9icH;zbZRqfmVicnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhYzOKXT3ofZBwgGGwdHjpcoUhfXC2YXvlJIFnfGW{IES4JIhzeyxiSVO1NEA:KDBwNDFOwG0v	NIK4UVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
red blood cells	MVXBcpRqdWGuYYLpZYwh[XO\|YYm=			NWG3OHU3SW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHCjcnHzbZRq[yCORFigZYN1cX[rdImgZpkhVWGuc4TheEBz\WGpZX70JIJie2WmIIPw[YN1em:yaH;0c41mfHKrYzDt[ZRpd2RuIFnDOVAhRSByLkSyJO69VS5?	NFjPWIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwNFQ2QCd-Mki4NFA1PTh:L3G+
red blood cells	M1\ycGFvfGmybHHzcY9lcWGuIHHzd4F6		MnLNO\|IhcHK\|	MV3BcpRqeGyjc33v[IlidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hXzJiaX7m[YN1\WRiaX6gdoVlKGKub3;kJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPYXzzeIF1KHKnYXflcpQh[mG\|ZXSgUGRJKGG\|c3H5MEBKSzVyIE2gNE41OyEQvF2u	M3vNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk5Lz5{OEOxOVU6QDxxYU6=
Vero	NIXZcIdCdnSrbXHsZZJq[WxiYYPzZZk>		NIDuV204OiCqcoO=	M2nI[2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hXzJiaX7m[YN1\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhMEOncnPvdIl1cGWldYOgZYV1cGmxcIOpJEhE\XKlb4DpeIhm[3W\|IHHleIhqd3C\|KTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KHCjcnHzbZRmKEyGSDDhZ5Rqfmm2eTDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjR6NDFOwG0v	M4fxd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEOzOVIxLz5zOUizN\|UzODxxYU6=
HEK293	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		NGHvZoc4OiCqcoO=	NXTYUYtRS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6g[JlmKGKjc3XkJIF{e2G7LDDJR\|UxKD1iMD60PUDPxE1w	M32wNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkO2OFkzLz5{OUKzOlQ6OjxxYU6=
red blood cells	NEPuUIpCdnSrbXHsZZJq[WxiYYPzZZk>		M4\4O\|czKGi{cx?=	M1vPN2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hXzJiaX7m[YN1\WRiaX6gbJVu[W5idInw[UBCNXCxc3n0bZZmKHKnZDDicI9w\CClZXzsd{Bie3Onc4Pl[EBieyCyYYLhd4l1\SCuYXP0ZZRmKGSnaInkdo9o\W6jc3WgZYN1cX[rdImgZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrczygTWM2OCB;IECuOVIh\|ryPLh?=	NWL5bWhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwOVQxOzhpPkKyNFU1ODN6PD;hQi=>
red blood cells	MWTBcpRqeGyjc33v[IlidCCjc4PhfS=>		NITq[lE1QCCqcoO=	NXj2eYJQSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDjbIxwem:zdXnu[U1z\XOrc4ThcpQhWGyjc33v[Il2dSCoYXzjbZBienWvIGeyJIlv\mWldHXkJIlvKGi3bXHuJJJm\CCkbH;v[EBk\WyuczDh[pRmeiB2ODDodpMh[nliU2nCVkB1\XO2LDDJR\|UxKD1iMD61PUDPxE1w	M{Gxb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUi4N\|A{Lz5{Nkm4PFMxOzxxYU6=
red blood cells	M2ThXGFvfGmvYXzhdolidCCjc4PhfS=>		Mlf4OFghcHK\|	NHTSZXBCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCvdXz0bYRzfWdvcnXzbZN1[W62IGDsZZNud2SrdX2g[oFt[2myYYL1cUBVVTl\|LVOxNFg5KGmwZnXjeIVlKGmwIHj1cYFvKE9icH;zbZRqfmVicnXkJIJtd2:mIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhYzOKXT3ofZBwgGGwdHjpcoUhfXC2YXvlJIFnfGW{IES4JIhzeyxiSVO1NEA:KDBwNkKg{txONg>?	NHP4WpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
Dd2	NEPJSZBCdnSrcHzhd41w\GmjbDDhd5NigQ>?			NVT3PVBtSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDkdpVoKHKnc3nzeIFvfCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gSIQzKHKrbnegd5Ri\2ViY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIIDhdoF{cXSnbXnhJIJ6KE2jbIP0ZZQh[XO\|YYmsJGlEPTBiPTCwMlcyKM7:TT6=	NVvsVnc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4OVg{ODBpPkKyPFU5OzByPD;hQi=>
red blood cells	M2SyNGFvfGmvYXzhdolidCCjc4PhfS=>		M{TDTVczKGi{cx?=	MWTBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJHczKGmwZnXjeIVlKGmwIILl[EBjdG:xZDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1mEUjDndoVmdiBzIIP0ZYlvcW6pIHLhd4VlKG[udX;yc41mfHKrYzDhd5NigSxiSVO1NEA:KDBwN{Wg{txONg>?	NIPUcJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5Nlg{OSd-Mke2PVI5OzF:L3G+
red blood cells	NIToVGFCdnSrbXHsZZJq[WxiYYPzZZk>		NXzmUFFJPDhiaILz	MYPBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\SxicInybY1mfGijbXnu[Uwh[W6mIH3l[oxweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCGZEKgbY5n\WO2ZXSgbY4hcHWvYX6gU{Bxd3OrdHn2[UBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN2heNWi7cH;4ZY51cGmwZTD1dJRic2ViYX\0[ZIhPDhiaILzMEBKSzVyIE2gNE46QCEQvF2u	NEDpdJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVU6Oyd-MkGxOVU2QTN:L3G+
HepG2	NUHDfmRZS3m2b4TvfIlkcXS7IHHzd4F6		NWfhWXBCPzJiaILz	NXXoN3BHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiZYjwdoV{e2mwZzDDSFgyKGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIu\2yxIHHzd4F6NCCFQ{WwJF0hOS54IN88UU4>	M2nUdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{mxOlc2Lz5{NUe5NVY4PTxxYU6=
HepG2	MYfBcpRqeGyjc33v[IlidCCjc4PhfS=>		MkDROFghcHK\|	M376WmFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RibHn2[ZIhe3SjZ3Wgc4YhWGyjc33v[Il2dSC7b3XsbYkhOTe[IF7MJJNxd3Kxen;peIV{KGmwZnXjeIVlKGmwIHj1cYFvKEincFeyJINmdGy\|IHX4dJJme3OrbnegR2Q5OSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZz3iZZNm\CCrbX31co9ndHWxcnXzZ4Vv[2ViYX7hcJl{cXNuIFnDOVAhRSBzLk[1JO69VS5?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MU[3OUc,OjV5OUG2O\|U9N2F-
WI38	MV\BcpRqfmm{YXygZZN{[Xl?		MUSyJIhzew>?	MVTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDCT3YhT2G{ZH7ldkBCXEOFIG\SPFM4KGmwZnXjeIVlKGmwIHj1cYFvKFeLM{igZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKH[rcnHsJGRPSSCuZY\lcEBxemWrbnP1ZoF1\WRiZn;yJFIhcHK\|IHLl[o9z\SC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgO{Bl[Xm\|IHL5JJJm[WxidHnt[UBRS1JiYYPzZZktKEWFNUCgQUAyNjdizszNMi=>	NGe4[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{i5N\|E2QCd-MUe4PVMyPTh:L3G+
HeLa	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGjLc2k1QCCqcoO=	M3f5V2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNFAhfU1iWn7DcFItKEeLNUCgQUAzNjFizszNMi=>	M2fSclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
SMB	M13KSWFvfGmycnnvckBie3OjeR?=			NIHrO2NCdnSrcILpc44h[WO2aY\peJkh[WejaX7zeEBEcGGwZHzldkB{fHKjaX6gc4Yhe2inZYCgd4Nz[XCrZTDwdolwdiCycn;0[YlvKGmwZnXjeIVlKGmwIH3veZNmKFOPQjDj[YxteyCjc4Pld5Nm\CCjczDjcIViemGwY3Wgc4Yh\Gm\|ZXHz[U1ie3OxY3nheIVlKHOlcnHwbYUheHKrb36gdJJwfGWrbjygSWM2OCB;IEKuN{DPxE1w	NEe4OYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NFg{Pyd-MkG1O\|A5Ozd:L3G+
HEK293	NIm4NZRHfW6ldHnvckBie3OjeR?=			NGraNmVKdmirYnn0bY9vKG:oIHj1cYFvKEWURzDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC2YXnsJIN2enKnboSgZZQhdWWvYoLhcoUheG:2ZX70bYFtKG:oIDuyNEBuXixiSVO1NEA:KDJwNTFOwG0v	MkXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NE[4NVYoRjJ3N{S2PFE3RC:jPh?=
red blood cells	NHn3NmZCdnSrbXHsZZJq[WxiYYPzZZk>		NWDEUYVTOjRiaILz	MXXBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2\|ZX7zbZRqfmViUHzhd41w\Gm3bTDmZYxkcXCjcoXtJFNFPyCrbn\lZ5Rm\CCrbjDy[YQh[myxb3SgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKG2jdIXy[UB{[2iren;ueJMh\m:{bXH0bY9vKGGodHXyJFI1KGi{czDifUBIcWWvc3Gtd5RicW6rbnegZoF{\WRiYYPzZZktKEWFNUCgQUAzNjl5IN88UU4>	MoOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFYoRjJ7NEm5OFg3RC:jPh?=
HEK293	NVjxfFJ2TnWwY4Tpc44h[XO\|YYm=			Mn\DbGVTTyCkaX7kbY5oKGG\|c3H5d\|ohTGm\|cHzhZ4Vu\W62IH;mJHs{UF1vRH;m[ZRqdGmmZTCoOUBvVSCoaX7hcEkh\nKxbTDoSXJIKG2nbXLyZY5meyCxYoThbY5m\CCocn;tJGhGUzJ7MzDj[YxteyxiS3mgQUA{NjF4MkK4JO69VS5?	NIrQ[VQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkO1N\|g2QSd-M{KzOVM5PTl:L3G+
1205 Lu	M2XzcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmDYO\|IhcHK\|	NV\yPJBlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTJyNTDMeUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz62JO69VS5?	NVT0[oVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVkyPTdpPkK1Olk6OTV5PD;hQi=>
LN229	MoG3R5l1d3SxeHnjbZR6KGG\|c3H5		NITGSZc4OiCqcoO=	M2LUfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPOjJ7IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	M4\3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm5NVU4Lz5{NU[5PVE2PzxxYU6=
C8161	Ml[2R5l1d3SxeHnjbZR6KGG\|c3H5		MmPzO\|IhcHK\|	MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDPFE3OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN{43KM7:TT6=	M4nnNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm5NVU4Lz5{NU[5PVE2PzxxYU6=
HT-29	NV;odFdTS3m2b4TvfIlkcXS7IHHzd4F6		MlTLO\|IhcHK\|	NI\McVhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy54IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7OUG1O{c,OjV4OUmxOVc9N2F-
WI38	NX;wXFJ7S3m2b4TvfIlkcXS7IHHzd4F6		NHjlXoUzPCCqcoO=	NYixTm9oS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hX0l\|ODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEOuOlMh\|ryPLh?=	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkGzNFkoRjJ3NE[xN\|A6RC:jPh?=
ScN2a	NVjs[lVDTnWwY4Tpc44h[XO\|YYm=			NH\BS3dJ[WyoIH3hfIlu[WxiaX7obYJqfGmxbjDv[kBRemmxbjDwdo91\WmwIGDyVJNkKG[xcn3heIlwdiC5YYOgZZN{[XmnZDDpckBU[05{YTDj[YxteyxiRVO1NEA:KDRizszNMi=>	M{PUN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUC0NFU6Lz5zMkmwOFA2QTxxYU6=
HepG2	NITSfnlEgXSxdH;4bYNqfHliYYPzZZk>		M4LNSFI1KGi{cx?=	M2jkfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFI1KGi{czDifUBv\XW2cnHsJJJm\CCmeXWgeZB1[WunIHHzd4F6NCCWQ{WwJF0hPC5\|IN88UU4>	M3r4OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{izPVg1Lz5{Mke4N\|k5PDxxYU6=
HeLa	NV3Rc4dmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2rjelQ5KGi{cx?=	M3\zOGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjC1NEB2VSCFdVPsNkwhT0l3MDC9JFQvPCEQvF2u	Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFYoRjF7N{S4O\|g3RC:jPh?=
HeLa	NEjJ[pRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2j1TlQ5KGi{cx?=	MXvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0hS3WFbEKsJGdKPTBiPTC1MlMh\|ryPLh?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4Okc,OTl5NEi3PFY9N2F-
HeLa	MnjHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVW0PEBpenN?	NHjY[FVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhcW5icILld4Vv[2Vib3[gOVAhfU1iWn7DcFItKEeLNUCgQUA2NjZizszNMi=>	NU\pVJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDZpPkG5O\|Q5Pzh4PD;hQi=>
HeLa	NGr2O\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXnpW4k2PDhiaILz	MmTvS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGgeW0hS3WFbEKsJGdKPTBiPTC2MlEh\|ryPLh?=	M1\XN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
SH-SY5Y	MmPvSpVv[3Srb36gZZN{[Xl?		NHG4eJUzPCCqcoO=	NHHFVVlOd2S3bHH0bY9vKG:oIHj1cYFvKHerbHSteJlx\SCDUGC2PVUh\XiycnXzd4VlKGmwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidXmub3nkJIJmfGFiKEGgeI8hPDBicnXzbYR2\XNrIIDyc4R2[3Srb36gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{NCCLQ{WwJF0hPyEQvF2u	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NUmxPVgoRjJ7NUW5NVk5RC:jPh?=
SH-SY5Y	M{TVN2Z2dmO2aX;uJIF{e2G7		NYHGT\|REOjRiaILz	NWnxS4N3UW6qaXLpeIlwdiCxZjDCRWNGOSCrbjDoeY1idiCVSD3TXVV[KGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSVCSNkm1JIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDhcZltd2mmIHLleIEhMDFidH:gOFAqKGyndnXsJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSCvZYToc4QtKEmFNUCgQUA4KM7:TT6=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ4OEiyNkc,OzB{Nki4NlI9N2F-
CHO	MnXXSpVv[3Srb36gZZN{[Xl?			NFvJXmRKdmirYnn0bY9vKG:oIHj1cYFvKEWURzDlfJBz\XO\|ZXSgbY4hS0iRIHPlcIx{NCCNaTC9JFcvPSEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[wN{c,OjR7MEC2NFM9N2F-
L6	NXfHR253S3m2b4TvfIlkcXS7IHHzd4F6			MmXrR5l1d3SxeHnjbZR6KGGpYXnud5QhVDZiY3XscJMtKEmFNUCgQUA4NjdizszNMi=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ6MEizOUc,OTd{OEC4N\|U9N2F-
HepG2	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		NVjNU3lIPzJiaILz	NYXUVpIxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hQC5\|IN88UU4>	M{Xr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OVk{Lz5{MUG1OVU6OzxxYU6=
WI38	NXXJUFZ{S3m2b4TvfIlkcXS7IHHzd4F6		MWeyJIhzew>?	M1TudmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdKOzhiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGy3bHHyJGRPSSCuZY\lcEBxemWrbnP1ZoF1\WRiZn;yJFIhcHK\|IHLl[o9z\SC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgO{Bl[Xm\|IHL5JJJm[WxidHnt[UBRS1JiYYPzZZktKEOFNUCgQUA5NjVizszNMi=>	NUTVbHJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PVMyPThpPkG3PFk{OTV6PD;hQi=>
HepG2	MY\BcpRqdWGuYYLpZYwh[XO\|YYm=			MXrBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEB{eG:{b4rvbZRmKHO2YXflJI9nKFCuYYPtc4RqfW1iYnXy[4hmcSC7b3XsbYkhcW6oZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVAhRSB7IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ2MEm4NUc,OjZ4NEC5PFE9N2F-
SKHep	MnS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3fuc\|Q5KGi{cx?=	NEDIcGlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0incDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFExLSCIQmOgd5VxeGynbXXueIVlKESPRV2gcYVlcXWvLDDHTVUxKD1iOT61JO69VS5?	MkXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFYoRjF7N{S4O\|g3RC:jPh?=
HeLa	Mme4R5l1d3SxeHnjbZR6KGG\|c3H5		MVy3JIhzew>?	NF;j[YlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhe3W{dnn2ZYwh[W[2ZYKgO{BpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPU43PjVizszNMi=>	Mmi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd5NkiwOVIoRjF5N{[4NFUzRC:jPh?=
HeLa	NF23TW5EgXSxdH;4bYNqfHliYYPzZZk>		MW[3JIRigXN?	MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeg[IF6eyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC5MlY4KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR6OUe4PUc,OjF2OEm3PFk9N2F-
K562	Mn7kR5l1d3SxeHnjbZR6KGG\|c3H5		NUC0bGZCOjRiaILz	Mn6xR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyC{YXTpc4FkfGm4ZTD0bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCjZoTldkAzPCCqcoOsJGNEPTBiPTC5Mlch\|ryPLh?=	M2Ow[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkiwNlc5Lz5zOE[4NFI4QDxxYU6=
Vero	MWHBcpRqfmm{YXygZZN{[Xl?		MY[2JJRwKDdiZHH5dy=>	M2HVd2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JINpcWu3bnf1cpliKH[rcoXzJGlv\GmjbjDvZ4VidiC\|dILhbY4hQDl7IHnu[oVkfGWmIHnuJHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjC2JJRwKDdiZHH5d{whTUN3MDC9JFExKM7:TT6=	NF\IfFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3NFU3OSd-MkW5O\|A2PjF:L3G+
PDAC	MlzDSpVv[3Srb36gZZN{[Xl?			NV73Xo5tUW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc4YhWESDQzDj[YxteyBqdX7rco94diCxcnnnbY4qNCCLQ{WwJF0hOTBizszNMi=>	NWq0fZlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|U1PzFpPkK2NVM2PDdzPD;hQi=>
Vero	M{XucGFvfGm4aYLhcEBie3OjeR?=		NFWyWoU3KHSxIEeg[IF6ew>?	MnPYRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgR4hqc3WwZ4XufYEhfmm{dYOgPFk6KGmwZnXjeIVlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHPlcIwh\GWjdHigZYZ1\XJiNjD0c{A4KGSjeYOgZpkhVVSVIHHzd4F6NCCHQ{WwJF0hOTBizszNMi=>	NVjifVNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlY5ODdpPkK0PVI3QDB5PD;hQi=>
HepG2	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEm2Oog1QCCqcoO=	MmrNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEWFNUCgQUAyOC5zIN88UU4>	MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6MEC4NlcoRjJ7OECwPFI4RC:jPh?=
BT-483	NYTab4xjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEDQS5A1QCCqcoO=	NUPBdItiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvNEizJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XliaX6gdJJme2WwY3Wgc4YhOTBnIF\CV{B{fXCybHXt[Y51\WRiRF3FUUBu\WSrdX2sJGdKPTBiPTCxNE4zKM7:TT6=	M2HpVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
Vero	NVzWbIY5SW62aY\pdoFtKGG\|c3H5		NH[wZYU2KGSjeYO=	NX76VXhVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJG9k\WGwIEi4PUBqdm[nY4Tl[EBqdiCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA2KGSjeYOgZpkhVVSVL2DNV{Bu\XSqb3SsJGVEPTBiPTCxNUDPxE1w	NGrpRng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOzOlk2OSd-MkmzN\|Y6PTF:L3G+
Vero A	NVPM[FJiSW62aY\pdoFtKGG\|c3H5		NHXUfJM3KHSxIEeg[IF6ew>?	NU\NdpQySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJI9k\WGwIIP0doFqdiB6OUmgbY5n\WO2ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliVnXyc{BCKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjD2bZJidC2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGGodHXyJFYhfG9iNzDkZZl{KGK7IF3UV{9RVVNiYYPzZZktKEWFNUCgQUAyOSEQvF2u	NWLWZoY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2O\|E5OzJpPkK4OlcyQDN{PD;hQi=>
Vero	MVXBcpRqfmm{YXygZZN{[Xl?		NUG0cGR2PSCmYYnz	NVrNXnlRSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJG9k\WGwIIP0doFqdiB6OUmgbY5n\WO2ZXSgbY4hSW[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtNWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5QhdWWjc4Xy[YQhd25iZHH5JFUheG:\|dDDpcoZm[3Srb36gZpkhVVSVL2DNV{Bie3OjeTygSWM2OCB;IEGxJO69VS5?	M3TFUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg4Lz5{OUS5PVQ5PzxxYU6=
Vero	Mne5RY51cX[rcnHsJIF{e2G7		NYSxdmh6PyCmYYnz	M1LxSGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNpcWu3bnf1cpliKH[rcoXzJGlv\GmjbjDPZ4VidiC\|dILhbY4hQDl7IHnu[oVkfGWmIHnuJGFnemmlYX6g[5Jm\W5ibX;ub4V6KF[ncn:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIFnfGW{IEeg[IF6eyCkeTDNWHMwWE2VIH3leIhw\CxiRVO1NEA:KDFzIN88UU4>	NYPU[3dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFA3OjZpPkK0PFAxPjJ4PD;hQi=>
Vero	NXPxPWxYSW62aY\pdoFtKGG\|c3H5		M1jjcFch\GG7cx?=	M{nw[WFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHNqdmSkaYOgeolzfXNic4TyZYlvKEiUc4CgbY5n\WO2ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{KGmwZIXj[YQh[2WubDDk[YF1cCCvZXHzeZJm\CCjZoTldkA4KGSjeYOsJGVEPTBiPTCxNUDPxE1w	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NkGxOkc,OjV7NE[xNVY9N2F-
Vero	NYDpWoJjSW62aY\pdoFtKGG\|c3H5		M1vWRlch\GG7cx?=	NXjWU2IxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhe3S{YXnuJFg6QSCrbn\lZ5Rm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOgbY5lfWOnZDDj[YxtKGSnYYToJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyxiRVO1NEA:KDFzIN88UU4>	M{jjeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS2NVE3Lz5{NUm0OlEyPjxxYU6=
Vero	NFrQW2VCdnSrdnnyZYwh[XO\|YYm=		NILyOFc3KHSxIEeg[IF6ew>?	NGSzVHNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBUcW6mYnnzJJZqenW\|IFjSd5AhcW6oZXP0[YQhcW5iQX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY3XscEBl\WG2aDDh[pRmeiB4IITvJFch\GG7czDifUBOXFNiYYPzZZktKEWFNUCgQUAyOSEQvF2u	NG[zdYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmyOlgxPyd-MkS5NlY5ODd:L3G+
Vero	NXy2fXBkSW62aY\pdoFtKGG\|c3H5		M2P3c\|YhfG9iNzDkZZl{	MVzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDTbY5l[mm\|II\pdpV{KEiUc4CgbY5n\WO2ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliVnXyc{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5QhcW6ldXLheIVlKG[xcjC2JJRwKDdiZHH5d{BjgSCPVGOgZZN{[XluIFXDOVAhRSBzMTFOwG0v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJzNUS2NEc,OjN{MUW0OlA9N2F-
Vero	M{e0bmFvfGm4aYLhcEBie3OjeR?=		MoqwOkB1dyB5IHThfZM>	M1rve2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGNpcWu3bnf1cpliKH[rcoXzJFg6QSCrbn\lZ5Rm\CCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBX\XKxIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDpcoN2[mG2ZXSg[o9zKDZidH:gO{Bl[Xm\|IHL5JG1VWyCjc4PhfUwhTUN3MDC9JFEyKM7:TT6=	NIXmSJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVQ3OCd-MkOyNVU1PjB:L3G+
red blood cells	MWnBcpRqdWGuYYLpZYwh[XO\|YYm=		NWf6dGNpPDhiaILz	MVLBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBkcGyxcn;xeYlv\S2{ZYPpd5RidnRiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGsyPCCrbn\lZ5Rm\CCrbjDoeY1idiC{ZXSgZoxwd2RiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHs{UF2qeYDvfIFvfGirbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFEyKM7:TT6=	NUnx[IVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPFIzPjBpPkK1NlgzOjZyPD;hQi=>
red blood cells	NYW5OolXSW62aX3hcIFzcWGuIHHzd4F6		M2PoNVI1KGi{cx?=	M1HZTGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGOqbH;yc5F2cW6nLYLld4l{fGGwdDDQcIF{dW:maYXtJIZidGOrcHHyeY0hWkuOOTDpcoZm[3SnZDDpckBz\WRiYnzvc4Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIH3heJVz\SC\|Y3jpfo9vfHNiZn;ycYF1cW:wIHHmeIVzKDJ2IHjyd{BjgSCJaXXtd4Eue3SjaX7pcoch[mG\|ZXSgZZN{[XluIFXDOVAhRSBzMT6yOUDPxE1w	M3i0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg3Lz5{OUS5PVQ5PjxxYU6=
MCF7	Mo[4R5l1d3SxeHnjbZR6KGG\|c3H5			NWPLXWI1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDbN2hecHmyb4jhcpRpcW6nIHnuZ49zeG:{YYTpc44tKEmFNUCgQUAyOiEQvF2u	M1LUZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUGyPVg4Lz5zOEWxNlk5PzxxYU6=
HEK293	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=		MnPuO\|IhcHK\|	NVTobXFWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNMkmzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDF{IN88UU4>	NVTKVHk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU2QTNpPkKxNVU2PTl\|PD;hQi=>
Vero	M3[xSmFvfGm4aYLhcEBie3OjeR?=		M1\4fFI1KGi{cx?=	NF34cYlCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBbcWujII\pdpV{KGmwZnXjeIVlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDSUmEhemWybHnjZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBu\XSqb3SsJGVEPTBiPTCxNkDPxE1w	Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyNki2NFQoRjJ6ME[4OlA1RC:jPh?=
Vero	Mn6wRY51cX[rcnHsJIF{e2G7		M1TocFI1KGi{cx?=	NGfOfmNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBbcWujII\pdpV{KGmwZnXjeIVlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JHZmem9iY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDSUmEhemWybHnjZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBu\XSqb3SsJGVEPTBiPTCxNkDPxE1w	M{PmXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEmyPFU6Lz5{OEC5Nlg2QTxxYU6=
HeLa	MV7BcpRqfmm{YXygZZN{[Xl?		MoCwOFghcHK\|	MnzYRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXOSCuZX70bZZqemGuIIDhdpRq[2ynczDpcoZm[3SnZDDpckBpfW2jbjDI[WxiKGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IIPw[YN1em:obIXvdo9u\XS{eTygTWM2OCB;IEGyMlQ5KM7:TT6=	NFTTdY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1PFMxOCd-MkK4OVg{ODB:L3G+
SH-SY5Y	M3nHUGZ2dmO2aX;uJIF{e2G7		M17lZ\|I1KGi{cx?=	MXPJcohq[mm2aX;uJI9nKEKDQ1WxJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDBVHA3QTViYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGGveXzvbYQh[mW2YTCoNUB1dyB2MjmgcIV3\WxiYX\0[ZIhOjRiaILzJIJ6KEWOSWPBJI1mfGixZDygTWM2OCB;IEGyMlch\|ryPLh?=	NWjtSJdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOlg5OjJpPkOwNlY5QDJ{PD;hQi=>
SH-SY5Y	MoLHSpVv[3Srb36gZZN{[Xl?		NU\RfIoxOjRiaILz	NEX0V\|dOd2S3bHH0bY9vKG:oIHj1cYFvKHerbHSteJlx\SCDUGC2PVUh\XiycnXzd4VlKGmwIGPIMXN[PVliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidXmub3nkJIJmfGFiKEGgeI8hPDJicnXzbYR2\XNrIIDyc4R2[3Srb36gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hOTJwODFOwG0v	M4HqXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUW5NVk5Lz5{OUW1PVE6QDxxYU6=
HepG2	M1nOOGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmOwO\|IhcHK\|	MlLVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcjDCcJVmKGG\|c3H5MEBKSzVyIE2gNVIvQSEQvF2u	MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzOUC4OVcoRjJzMUmwPFU4RC:jPh?=
Vero	NF32ZnhCdnSrdnnyZYwh[XO\|YYm=		NHuxRWY3KHSxIEeg[IF6ew>?	M3Wx[GFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHNmdWyra3mg[o9z\XO2II\pdpV{KF[rZYTuZY0hcW6oZXP0[YQhcW5iQX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY3XscEBl\WG2aDDh[pRmeiB4IITvJFch\GG7czDifUBOXFNiYYPzZZktKEWFNUCgQUAyOy56IN88UU4>	NXLjflFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlY5ODdpPkK0PVI3QDB5PD;hQi=>
Vero	M4DZ[2FvfGm4aYLhcEBie3OjeR?=		M1rqb\|ch\GG7cx?=	NX7lZphJSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhW2WvbHnrbUBnd3Knc4SgeolzfXNic4TyZYlvKF[rZYTuZY0hcW6oZXP0[YQhcW5iYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|IHnu[JVk\WRiY3XscEBl\WG2aDDt[YF{fXKnZDDh[pRmeiB5IHThfZMtKEWFNUCgQUAyPCEQvF2u	M4mwNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS2NVE3Lz5{NUm0OlEyPjxxYU6=
Vero	Mm\6RY51cX[rcnHsJIF{e2G7		NIfEVWc3KHSxIEeg[IF6ew>?	MV;BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDT[Y1tcWurIH\vdoV{fCC4aYL1d{Bqdm[nY4Tl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCrbnP1ZoF1\WRiZn;yJFYhfG9iNzDkZZl{KGK7IF3UV{Bie3OjeTygSWM2OCB;IEG0JO69VS5?	M4fzd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1OFYxLz5{M{KxOVQ3ODxxYU6=
NSO	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=			NVnQSYoxS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVlORIHPlcIx{KGK7IF3UWEBie3OjeTygWGM2OCB;IEG0Mlkh\|ryPLh?=	NFfjN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxN\|k2PSd-MUmxNVM6PTV:L3G+
L1210	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=			NHXI[lNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCkeTDDc5VtfGW{IHPveY51\XJiYX7hcJl{cXNuIFnDOVAhRSBzNTFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNEixNUc,OjZzMUS4NVE9N2F-
Huh-7	M1;BSGFvfGmybHHzcY9lcWGuIHHzd4F6		Ml\yOFghcHK\|	NVXWNGozSW62aYDsZZNud2SrYXygZYN1cX[rdImgZYdicW6\|dDDQcIF{dW:maYXtJIJmemeqZXmgcIl3\XJic4Th[4Uh\m:{bTD0doFve2[nY4Tl[EBqdiCqdX3hckBJfWhvNzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMUWuPUDPxE1w	MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{N{OwN\|goRjJ\|MkezNFM5RC:jPh?=
Daudi	NE\BcYpEgXSxdH;4bYNqfHliYYPzZZk>			M3\vXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRifWSrIHPlcIx{KGK7IF3UWEBie3OjeTygWGM2OCB;IEG2Mlch\|ryPLh?=	M1PaWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUGzPVU2Lz5zOUGxN\|k2PTxxYU6=
HeLa	NXq5fmxXS3m2b4TvfIlkcXS7IHHzd4F6			MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIJ6KEOxdXz0[ZIh[2:3boTldkBidmGueYPpd{whUUN3MDC9JFE5KM7:TT6=	MnrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUS4NVEoRjJ4MUG0PFEyRC:jPh?=
J774.1	NXjtOYh4S3m2b4TvfIlkcXS7IHHzd4F6		M3LYfVI1KGi{cx?=	MkTYR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgTlc4PC5zIHPlcIx{KGGodHXyJFI1KGi{czDifUBCdGGvYYLCcJVmKGKjc3XkJIN6fG:2b4jpZ4l1gSCjc4PhfUwhUUN3MDC9JFE5NjRizszNMi=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzNzNkW0Nkc,Ojd\|MU[1OFI9N2F-
HeLa	NEfZZWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NET5dZU1QCCqcoO=	M1TW[mdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVIIP1dJBt\W2nboTl[EBFVUWPIH3l[Il2dSxiR1m1NEA:KDF6Lk[g{txONg>?	NWn6Vo81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFg4QDZpPkG5O\|Q5Pzh4PD;hQi=>
MCF7	NEDPdmZEgXSxdH;4bYNqfHliYYPzZZk>		M1ToS\|Q5KGi{cx?=	Ml;vR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBESzVyIE2gNVkvPCEQvF2u	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODBzNEi1O{c,OjByMUS4OVc9N2F-
MCF7	M1X3cWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2HvOlQ5KGi{cx?=	Moi4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKHKnZIXjeIlwdiCjc4PhfUwhS0N3MDC9JFE6NjRizszNMi=>	M{XXfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki2NFE{Lz5{NE[4OlAyOzxxYU6=
MCF7	NXLCbIptS3m2b4TvfIlkcXS7IHHzd4F6		M4jQSlQ5KGi{cx?=	M3jtWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiQ1O1NEA:KDF7LkSg{txONg>?	M1uzOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm0OVI1Lz5{NEW5OFUzPDxxYU6=
MDA-MB-468	NXPJWnNSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWm3NkBpenN?	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFE6Njh4IN88UU4>	NXmyNGhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NFI5OjdpPkK2OlAzQDJ5PD;hQi=>
KB	NHnEWY5EgXSxdH;4bYNqfHliYYPzZZk>		NUPpW4pFPDhiaILz	MmPGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKwMlQh\|ryPLh?=	NVO1OYI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG4NFkxPzVpPkGxPFA6ODd3PD;hQi=>
Vero	NXTWTWtxSW62aY\pdoFtKGG\|c3H5		M2fHPVUh\GG7cx?=	NVnCTnpRSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhS2ira4Xu[5VvgWFidnnyeZMhUW6maXHuJG9k\WGwIEi4PUBqdm[nY4Tl[EBqdiCDZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA2KGSjeYOgZpkhVVSVL2DNV{Bu\XSqb3SsJGVEQTBiPTCyNUDPxE1w	NVrqOFNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN\|Y6PTFpPkK5N\|M3QTVzPD;hQi=>
Vero	NETvPW9CdnSrdnnyZYwh[XO\|YYm=			MnrjRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgR4hqc3WwZ4XufYEhfmm{dYOgTY5lcWGwIF;j[YFvKHO2cnHpckA5QTliaX7m[YN1\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgcYVie3W{ZXSgc44h\GG7IEWgdI9{fCCrbn\lZ5Rqd25iYomgUXRUN1CPUzDhd5NigSxiRVO5NEA:KDJzIN88UU4>	NU\1bIFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDdpPkK5OFk6PDh5PD;hQi=>
Vero	MmOxRY51cX[rcnHsJIF{e2G7		M{L5[lch\GG7cx?=	NH7sVXpCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBEcGmtdX7neY56[SC4aYL1d{BKdmSrYX6gU4Nm[W5ic4TyZYlvKDh7OTDpcoZm[3SnZDDpckBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjC3JIRigXNiYomgUXRUN1CPUzDt[ZRpd2RuIFXDPVAhRSB{MTFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyME[yOkc,OjR6MEC2NlY9N2F-
Vero	Mm\SR5l1d3SxeHnjbZR6KGG\|c3H5		MoLqO\|IhcHK\|	NI\GeXVEgXSxdH;4bYNqfHliYXfhbY5{fCCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDW[ZJwKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAzOSEQvF2u	M3XyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K3OVM5Lz5{M{eyO\|U{QDxxYU6=
HepG2	MmfxR5l1d3SxeHnjbZR6KGG\|c3H5		Moj5OFghcHK\|	NYLXcHVZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KGyjY4TheIUh\GWqeXTyc4dmdmG\|ZTDhd5NigSxiR1m1NEA:KDJ{LkG2JO69VS5?	M2jSS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEiyPFMyLz5{MUi4Nlg{OTxxYU6=
KB	M1jFTGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mmm3O\|IhcHK\|	NF;3V49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNlIvPSEQvF2u	NFnR[5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi3PVE2OCd-MUm4O\|kyPTB:L3G+
MDA-MB-231	M2jyWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1S2blQ5KGi{cx?=	M2PS[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IEKyMlUzKM7:TT6=	MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MES5O\|koRjF7OEC0PVc6RC:jPh?=
MDA-MB-231	NXroO\|Q5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGPwd4U1QCCqcoO=	NFPRW21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIIC1N{wheFKEIH31eIFvfCCjbnSg[ZN1em:pZX6gdoVk\XC2b4Kg[IVncWOrZX70JG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OCB;IEKyMlUzKM7:TT6=	M1;POVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNU[xO\|IxLz5{MEW2NVczODxxYU6=
MDA-MB-231	NV3Wb2NNS3m2b4TvfIlkcXS7IHHzd4F6		NVTWTWJQPDhiaILz	NFG0WohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAzOi53MjFOwG0v	M3yxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUi2O\|E3Lz5{OEW4OlcyPjxxYU6=
CEM	NVvhTW1DS3m2b4TvfIlkcXS7IHHzd4F6			MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZpkhS2:3bITldkBkd3WwdHXyJIFv[Wy7c3nzMEBKSzVyIE2gNlMh\|ryPLh?=	MmjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUS4NVEoRjJ4MUG0PFEyRC:jPh?=
CE81T	NIi2elRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXq0PEBpenN?	MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDSVgyXCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5JIlvKHC{ZYPlcoNmKG:oIEGwKUBHSlNic4XwdIxmdWWwdHXkJGROTU1ibXXkbZVuNCCJSUWwJF0hOjNwNDFOwG0v	M4\ZOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O\|g3Lz5zOUe0PFc5PjxxYU6=
MCF7	NELG[YxEgXSxdH;4bYNqfHliYYPzZZk>		M{HDR\|czKGi{cx?=	NXf1TpBlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDueY1j\XJiaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCyN{41OyEQvF2u	NI\YeIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOVQ4OSd-Mk[xN\|U1PzF:L3G+
HepG2	Mnz0R5l1d3SxeHnjbZR6KGG\|c3H5		NGDLVnE4OiCqcoO=	MmThR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiaX70doFk\WyudXzhdkBCXFBibHX2[Ywh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGy2aYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFXDOVAhRSB{NTFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlzMES2Okc,OjF7MUC0OlY9N2F-
HepG2	NFTEUm5EgXSxdH;4bYNqfHliYYPzZZk>		M3PlSFczKGi{cx?=	NWrCOXhUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygcpVu[mW{IHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNlUh\|ryPLh?=	M1rlRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO1OFcyLz5{NkGzOVQ4OTxxYU6=
BxPC3	M3XTbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M37wSFczKGi{cx?=	M4jVWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQojQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBu\XSqb3SsJGlEPTBiPTCyOUDPxE1w	M{GwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm5NVU4Lz5{NU[5PVE2PzxxYU6=
MDA-MB-468	NYDZbJJTS3m2b4TvfIlkcXS7IHHzd4F6		NHT1[JY1QCCqcoO=	NWS1[nRPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNlgvPThizszNMi=>	NHLvUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOFk4QSd-MUm4NFQ6Pzl:L3G+
MDA-MB-468	NFH2OVhEgXSxdH;4bYNqfHliYYPzZZk>		MWO0PEBpenN?	NHPze\|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCyPE42QCEQvF2u	MnrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzME[2OlgoRjJyMUC2OlY5RC:jPh?=
MDA-MB-468	M4X6bmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUXzblBEPDhiaILz	Ml\QR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNlgvPThizszNMi=>	NV3KfYFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OTZpPkK4OVg3PzF4PD;hQi=>
K562	MlvaR5l1d3SxeHnjbZR6KGG\|c3H5			NV;xTGtpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyPU4xOyEQvF2u	NYf4Tm9VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlIzODJpPkG4OVYzOjB{PD;hQi=>
HeLa	M4HhWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2\BR\|czKGi{cx?=	NIHMNVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEK5Mlk3KM7:TT6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZyMkiyO{c,OjZ4MEK4Nlc9N2F-
HepG2	M3m2eGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MX23NkBpenN?	MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|Ah\|ryPLh?=	NXjnR4tYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0PFI1PzZpPkG5OFgzPDd4PD;hQi=>
HepG2	MnTxR5l1d3SxeHnjbZR6KGG\|c3H5		MV:3NkBpenN?	MlXvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFMxKM7:TT6=	MmrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Mk[xO\|MoRjF7OUK2NVc{RC:jPh?=
HepG2	MlTTR5l1d3SxeHnjbZR6KGG\|c3H5			NH3Cd3REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzNEDPxE1w	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl6MUS2Nkc,OTd7OEG0OlI9N2F-
HepG2	MnHxR5l1d3SxeHnjbZR6KGG\|c3H5		M4nUOFczKGi{cx?=	NWfnUZV2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNyIN88UU4>	NXXvVYVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OFEyOzFpPkKxO\|QyOTNzPD;hQi=>
HepG2	NV;RVGVjS3m2b4TvfIlkcXS7IHHzd4F6		MXK3NkBpenN?	NVLDb5ozS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNyIN88UU4>	MlzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6OEm1OVkoRjJ{OEi5OVU6RC:jPh?=
HepG2	NGGybmpEgXSxdH;4bYNqfHliYYPzZZk>		NFnoV2I4OiCqcoO=	MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBESzVyIE2gN\|Ah\|ryPLh?=	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVYoRjJ2OUS2NlE3RC:jPh?=
SH-SY5Y	Mor1R5l1d3SxeHnjbZR6KGG\|c3H5		MVK3NkBpenN?	MmnUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOzBizszNMi=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV3OUG5PEc,Ojl3NUmxPVg9N2F-
HepG2	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		NVLSU5c2PzJiaILz	MmfyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFMxKM7:TT6=	NX;HVm5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OVg2PDNpPkK0PFU5PTR\|PD;hQi=>
HepG2	M4K0WmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGTWUnQ4OiCqcoO=	MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBESzVyIE2gN\|Ah\|ryPLh?=	M4HjNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY{Lz5{N{G1OVQ3OzxxYU6=
HepG2	MkjBR5l1d3SxeHnjbZR6KGG\|c3H5		MUS3NkBpenN?	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBESzVyIE2gN\|Ah\|ryPLh?=	NITKVnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NVY4PSd-MkW3PVE3PzV:L3G+
HepG2	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		MXy3NkBpenN?	MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGNEPTBiPTCzNEDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ6MkK2O{c,OjV{OEKyOlc9N2F-
HepG2	NVXEU3F2S3m2b4TvfIlkcXS7IHHzd4F6		Ml;IO\|IhcHK\|	M{X4PWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUCgQUA{OCEQvF2u	NED6XHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi1NlE{Oid-MkG4OVIyOzJ:L3G+
HepG2	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		NFnheII4OiCqcoO=	M1q5[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEOFNUCgQUA{OCEQvF2u	NWG1SWE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NFg3PzVpPkKyOlA5Pjd3PD;hQi=>
HepG2	M{PBcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWjRcWRUPzJiaILz	MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDNyIN88UU4>	NIPr[I09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[1OFM6PSd-Mke2OVQ{QTV:L3G+
KB	NGn0fJJEgXSxdH;4bYNqfHliYYPzZZk>			MkXZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZpkhW1KEIHHzd4F6NCCHREWwJF0hOzBwODFOwG0v	NW\5bVg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[1OlI5OzJpPkG2OVYzQDN{PD;hQi=>
HepG2	M4jjc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MkewNlQhcHK\|	NG\xTZFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhdmW3dILhcEBz\WRidYD0ZYtmKGG\|c3H5MEBVSzVyIE2gN\|Eh\|ryPLh?=	NWT6VWpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFU5OTZpPkKzNVQ2QDF4PD;hQi=>
K562	NILLN4lEgXSxdH;4bYNqfHliYYPzZZk>		NHXzUI04OiCqcoO=	NIC0e\|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IEOyJO69VS5?	Mof2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2OEK0O\|YoRjF7NEiyOFc3RC:jPh?=
K562	NXvwfYp7S3m2b4TvfIlkcXS7IHHzd4F6		M{\xPFczKGi{cx?=	NVzvTVNWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkh\myxdzDjfZRwdWW2comsJGlEPTBiPTCzNkDPxE1w	MlzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Mk[xO\|MoRjF7OUK2NVc{RC:jPh?=
FM3A	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3veZNmKG2jbX3hdpkhfHWvb4KgSm0{SSClZXzsd{whTUN3MDC9JFMzKM7:TT6=	NYXWdmZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5OlY4PDZpPkGwPVY3PzR4PD;hQi=>
FM3A	NInBSmFEgXSxdH;4bYNqfHliYYPzZZk>			NVm1UYVDUW5idnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWGvbXHyfUBHVTODIHPlcIx{NCCHQ{WwJF0hOzJizszNMi=>	MkLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJyM{[zOlUoRjF{MEO2N\|Y2RC:jPh?=
FM3A	MnHuR5l1d3SxeHnjbZR6KGG\|c3H5			MlrUR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgcYFudWG{eTD0eY1weiCITUPBJINmdGy\|IILldJJme2WwdHnu[{BiKG2xZHXsJI9nKGixc4SsJGVEPTBiPTCzNkDPxE1w	NFrSc2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUi1OVk4QCd-MUG4OVU6Pzh:L3G+
FM3A	NFixUVREgXSxdH;4bYNqfHliYYPzZZk>			MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBHVTODIH3veZNmKG2jbX3hdpkh[2WubIOsJGVEPTBiPTCzNkDPxE1w	NUHDTIhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUO2O\|g1OTNpPkGzOlc5PDF\|PD;hQi=>
FM3A	MlL2R5l1d3SxeHnjbZR6KGG\|c3H5		NYLvbVRrPDhiaILz	NV7kbWN6S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTk1\|QTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGmwY4LlZZNmKGmwIHPlcIwh\GWwc3n0fUBi\nSncjC0PEBpenNuIFXDOVAhRSB\|MjFOwG0v	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR5OUmyOkc,OTh2N{m5NlY9N2F-
FM3A	M3vPXGN6fG:2b4jpZ4l1gSCjc4PhfS=>			MUHDc41xd3WwZDD3ZZMhfGW\|dHXkJIZweiCleYTveI95cWOrdImgZYdicW6\|dDDGUVNCKG2xdYPlJI1idW2jcomgZ4VtdHNwIDygSWM2OCB;IEOyJO69VS5?	MlnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2NEe5OlEoRjFyNES3PVYyRC:jPh?=
LNCAP	M3LIfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{TpbFczKGi{cx?=	M4XpemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuIH71cYJmeiCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IEOyMlg4KM7:TT6=	NUnqcWtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|U1PzFpPkK2NVM2PDdzPD;hQi=>
HCT116	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MoOxO\|IhcHK\|	NF3TSWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEGgZZN{[XluIFnDOVAhRSB\|Mz63JO69VS5?	M1LQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{M{m4OVMyLz5zMkO5PFU{OTxxYU6=
KB	M4TjTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnT1O\|IhcHK\|	NX3t[md3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhTUR3MDC9JFM{NjdizszNMi=>	NI\R[ZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OUG3Nlg{Lz57OUG3Nlg{RC:jPh?=
KB	M2n1emN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXniR5BsPzJiaILz	MkHXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iM{Sg{txONg>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEeyOEc,OjR7MEC3NlQ9N2F-
CHO	NHfaS3FEgXSxdH;4bYNqfHliYYPzZZk>			MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBEUE9iY3XscJMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{WuPEDPxE1w	M2DKc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEOyNlIzLz5{NkizNlIzOjxxYU6=
KB	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=			MkjUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44tKEmFNUCgQUA{PS57NTFOwG0v	NWrwZ4dVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NFUzOjBpPkKxO\|A2OjJyPD;hQi=>
MCF7	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		MmL3OFghcHK\|	M1i0T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFM3NjFizszNMi=>	Mm\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUK1OVQoRjF7OEmyOVU1RC:jPh?=
MDA-MB-231	NEDEOIpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYK3NkBpenN?	M3vSbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOzZwNUOg{txONg>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZyMkiyO{c,OjZ4MEK4Nlc9N2F-
NFF	NGTreFlEgXSxdH;4bYNqfHliYYPzZZk>		NUW1bmF[OyCmYYnz	MkfpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmZHKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOzdwMzFOwG0v	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMUexO\|AoRjJ\|MUG3NVcxRC:jPh?=
MCF7	MlXYR5l1d3SxeHnjbZR6KGG\|c3H5		NYr2Xng2PDhiaILz	MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCzPE41PCEQvF2u	NH;zVG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOFk4QSd-MUm4NFQ6Pzl:L3G+
MCF7	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		MWi0PEBpenN?	NFPmW4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUA{QC52NDFOwG0v	Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzME[2OlgoRjJyMUC2OlY5RC:jPh?=
p53+/- MCF7	NFvRcWZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1eyOlQ5KGi{cx?=	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKHB3MzuvMUBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUCgQUA{QC52NDFOwG0v	NWe5UHE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OlE4OjBpPkKwOVYyPzJyPD;hQi=>
MCF7	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml\rOFghcHK\|	MlXHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOzhwNESg{txONg>?	MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OE[3NVYoRjJ6NUi2O\|E3RC:jPh?=
Caco2	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4LJZ\|Ih\GG7cx?=	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjY3:yJINmdGy\|IHHmeIVzKDJiZHH5d{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyIE2gN\|gvPjdizszNMi=>	NUm2TYtTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQxPzZpPkK0NVg1ODd4PD;hQi=>
THP1	NVfUNnhLS3m2b4TvfIlkcXS7IHHzd4F6			MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUTHAyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRyIN88UU4>	NGezSFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m4NVQ3Oid-MUe5PFE1PjJ:L3G+
THP1	NHO0[lZEgXSxdH;4bYNqfHliYYPzZZk>		MojvO\|IhcHK\|	MoXPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWGhROSClZXzsd{Bi\nSncjC3NkBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTyfUwhUUN3MDC9JFQxKM7:TT6=	MkjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFEoRjF7N{S4O\|gyRC:jPh?=
THP1	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=		NX3VVVRPPzJiaILz	M{HyOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHRJWDFiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gOFAh\|ryPLh?=	M2\KUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0O\|Q4Lz5zOUmxOFc1PzxxYU6=
THP1	NYDxSIVpS3m2b4TvfIlkcXS7IHHzd4F6		Mk\4O\|IhcHK\|	NGTXVlJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVUFBzIHPlcIx{KHW\|aX7nJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZYZ1\XJiN{KgbJJ{KGK7IH\sc5ch[3m2b33leJJ6NCCLQ{WwJF0hPDBizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ\|OEi1OEc,OjB4M{i4OVQ9N2F-
HEK293	MmDjR5l1d3SxeHnjbZR6KGG\|c3H5		NYOwRYtNPzJiaILz	NGThc\|dEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSB2MDFOwG0v	NVnYSJk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O\|Q1OjdpPkK4O\|c1PDJ5PD;hQi=>
NCH-89	M3TZUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUK0PEBpenN?	NGPlOFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPhdo12e3SrbnWtdoV{cXO2YX70JG5EUC16OTDj[YxteyCjc4Pld5Nm\CCjczDCdoRWKGmwY3;ydI9z[XSrb36gZYZ1\XJiNEigbJJ{NCCLQ{WwJF0hPDFwMjFOwG0v	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN{OUezN{c,OjB\|Mkm3N\|M9N2F-
HepG2	NGTuVnlEgXSxdH;4bYNqfHliYYPzZZk>		MWK0PEBpenN?	M2DvOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KEyGSDDhd5NigSxiR1m1NEA:KDR\|LkC5JO69VS5?	NHXZW5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4OFQzOid-MkW2PFQ1OjJ:L3G+
L6	NFLlWZJVd3irY3n0fUBie3OjeR?=			NGC2VoNVd3irY3n0fUBi\2GrboP0JJJifCCONjDj[YxteyxiSVO1NEA:KDR\|LkGg{txONg>?	MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5OEG5OFgoRjF7N{ixPVQ5RC:jPh?=
KB	MojnR5l1d3SxeHnjbZR6KGG\|c3H5		MU[3NkBpenN?	MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFPDOVAhRSB2NDFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODBzNEi1O{c,OjByMUS4OVc9N2F-
MKN28	MkHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYSyJIRigXN?	NIjXbpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlI5KGOnbHzzJIFnfGW{IEKg[IF6eyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hPDRwNESg{txONg>?	NFvaVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFA4Pid-MkSxPFQxPzZ:L3G+
NFF	M3KwWmN6fG:2b4jpZ4l1gSCjc4PhfS=>			NETYfFREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPTkZiY3XscJMtKEmFNUCgQUA1Pi54MEig{txONg>?	M4DGUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS1OFAzLz5\|MEK0OVQxOjxxYU6=
J774	MlSxR5l1d3SxeHnjbZR6KGG\|c3H5		MV:3NkBpenN?	NHT2V41EgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBLPzd2IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuQTZiYYH1[Y92eyCxbnWgd49tfXSrb36gZ4VtdCCycn;sbYZmemG2aX;uJIF{e2G7LDDFR\|UxKD1iNEeuNkDPxE1w	M2jKeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkG1Nlc6Lz5{OUKxOVI4QTxxYU6=
HEK293	M4nwcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXXjdZV6PzJiaILz	M4f5bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFzKEKudXWgZZN{[XluIFnDOVAhRSB2ODFOwG0v	NXjPWnU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxPVA5PTdpPkKxNVkxQDV5PD;hQi=>
MRC5	MmPxR5l1d3SxeHnjbZR6KGG\|c3H5			MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBOWkN3IHPlcIx{	MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzNk[3NVgoRjF5MU[2O\|E5RC:jPh?=
HeLa	MUnGeY5kfGmxbjDhd5NigQ>?	NX7ucXp1OTBidV2=	NULicY5TOSCqch?=	MWHTeIlufWyjdHnvckBw\iC{ZXHjeIl3\SCxeInn[Y4he3CnY3nld{BqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IEGwJJVOKGmwIIDy[ZNmdmOnIH;mJFExKHWPIFP1R4wzKGGodHXyJFEhcHJiYomg[IlpgWS{b3X0bIllcXWvIHT5[UBj[XOnZDDmcJVwemW\|Y3XuZ4Uh[XO\|YYm=	MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEi3PFYoRjF7N{S4O\|g3RC:jPh?=
A673	MlfOdWhVWyCjc4PhfS=>			NHXGSVlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NELCNpZyUFSVIHHzd4F6			NFTGbWxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	M{[zb5FJXFNiYYPzZZk>			M3j0dpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	Moj0dWhVWyCjc4PhfS=>			MorodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NH6zeng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MUnxTHRUKGG\|c3H5			M3zyNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NFPL[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	NXKzXVZVeUiWUzDhd5NigQ>?			MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MlnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NVrQXo1VeUiWUzDhd5NigQ>?			MoKwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	M4\JV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MnnGdWhVWyCjc4PhfS=>			MnvZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NU\ROpN7eUiWUzDhd5NigQ>?			NEXNSlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NX3BPVFHeUiWUzDhd5NigQ>?			MknQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NFnrPWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MlHkdWhVWyCjc4PhfS=>			NIO4ZVlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
HEK293	M3XtPGF2fG:yaHHnfUBie3OjeR?=	MX[xNEB2VQ>?	NEK2fW85KGi{cx?=	M134[mlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJA3OiCuZY\lcEBifCBzMDD1UUBi\nSncjC4JIhzeyCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6MUWzOkc,Ojh2OEG1N\|Y9N2F-
HEK293	NGD4XodCfXSxcHjh[5kh[XO\|YYm=	Mlm5NVAhfU1?	NH34Omk5KGi{cx?=	NYn0SYk3UW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVEN\|LUKgcIV3\WxiYYSgNVAhfU1iYX\0[ZIhQCCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NUXrWGNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFE2OzZpPkK4OFgyPTN4PD;hQi=>
LNCAP	M3rTTWZ2dmO2aX;uJIF{e2G7			MWjS[YR2[3Srb36gbY4hT0[SIHX4dJJme3Orb36gbY4hcHWvYX6gUG5ESVBiY3XscJMhfHKjboPm[YN1\WRid3n0bEBxdGG\|bXnkd{Bkdy2neIDy[ZN{cW6pIFfGVEBidmRic3jSUmF{KGGpYXnud5QhWkWYLVXSRoJmfGFiZn;scI94\WRiYomgZ49ueG:3bnSgeJJm[XSvZX70JFI1KGi{czDwc5N1NXS{YX7z[oVkfGmxbjDhcoQhdWWjc4Xy[YQhPDhiaILzJJBwe3RiZH;z[S=>	MmrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{W0O\|EoRjJ4MUO1OFcyRC:jPh?=
SKBR3	NEflWHFHfW6ldHnvckBie3OjeR?=			NF\ZR\|lT\WS3Y4Tpc44hcW5iR1\QJIV5eHKnc4Ppc44hcW5iaIXtZY4hW0uEUkOgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCybHHzcYlleyClbz3lfJBz\XO\|aX7nJGdHWCCjbnSgd4hTVkG\|IHHnZYlve3RiUlXWMWVTSmKndHGg[o9tdG:5ZXSgZpkh[2:vcH;1coQhfHKnYYTt[Y51KDJ2IHjyd{Bxd3O2LYTyZY5{\mWldHnvckBidmRibXXhd5Vz\WRiNEigbJJ{KHCxc4Sg[I9{\Q>?	M1fxNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO1OFcyLz5{NkGzOVQ4OTxxYU6=
HepG2	NF3oTWVHfW6ldHnvckBie3OjeR?=			Ml\FVoVlfWO2aX;uJIlvKEeIUDDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmeEd{IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[JMh[29vZYjwdoV{e2mwZzDHSnAh[W6mIIPoVm5CeyCjZ3HpcpN1KFKHVj3FVmJj\XSjIH\vcIxwf2WmIHL5JINwdXCxdX7kJJRz\WG2bXXueEAzPCCqcoOgdI9{fC22cnHud4Zm[3Srb36gZY5lKG2nYYP1doVlKDR6IHjyd{Bxd3O2IHTvd4U>	NFHVXFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOVQ4OSd-Mk[xN\|U1PzF:L3G+
H460	MXjBdI9xfG:\|aYOgZZN{[Xl?	NIK4U4czPSC2bzC3OUB2VQ>?	NYfDd4RyOjRiaILz	MXXJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYSgNlUhfG9iN{WgeW0h[W[2ZYKgNlQhcHK\|IHL5JIFvdmW6aX6tWkB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	NUCyeI9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVkyPTdpPkK1Olk6OTV5PD;hQi=>
HepG2	M3Tle2Z2dmO2aX;uJIF{e2G7	Mmj0OVAhfU1?	NF:xU\|M3KGi{cx?=	NYHTZWhwWmWmdXP0bY9vKGmwIHz5d49{d22jbDDhZ4llcW[rY3H0bY9vKGmwIHj1cYFvKEincFeyJINmdGy\|IHH0JFUxKHWPIHHmeIVzKDZiaILzJIJ6KESDUFmvcJl{dyC2cnHjb4VzKHKnZD3kc5VjdGVic4ThbY5qdmdiYnHz[YQh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7N{OyNEc,OjhzOUezNlA9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ZEBRA / p-S824 KAP1 ; PubMed: 28249048 PLoS Pathog HH514-16 BL cells were treated with chloroquine and harvested at different times post-treatment for immunoblotting with antibodies as indicated. p62 / LC3 ; PubMed: 26677873 Proc Natl Acad Sci U S A Antiautophagic activity of Lys01. Panc 10.05 cells were treated for 24 h with the indicated doses of chloroquine or Lys01 and were probed by Western blot.	28249048 26677873
Immunofluorescence	p-S824 KAP1 / ZEBRA ; PubMed: 28249048 PLoS Pathog HH514-16 BL cells were treated with chloroquine (CQ) or chloroquine plus KU-55933 (CQ+KU) and harvested at 24 hours followed by staining with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification. CD1d-β2m / LAMP1 ; PubMed: 20368272 J Immunol HEK293-CD1d WT cells were treated overnight with 20 μM of chloroquine (or vehicle). The cells were then fixed, permeabilized and stained with the anti-CD1d-β2m mAb (red), anti-LAMP-1 (green) and Hoechst (blue). The stained cells were then analyzed by confocal microscopy. SQSTM1 / MAP1LC3B ; PubMed: 29872540 Cell Discov Immunofluorescent images of astrocytoma SNB-19 cells treated with DMSO, emetine or chloroquine for 24 h, then stained with SQSTM1 protein (green), MAP1LC3B protein (red) and nuclei (blue).	28249048 20368272 29872540
Growth inhibition assay	Cell viability ; PubMed: 25521075 Br J Pharmacol A549 cells were treated with serial concentrations of chloroquine for 72 h, and Huh7 cells were treated with the same concentrations for 48 h. Tumour cell viability was determined by cell viability assay. Data represent means from at least three independent experiments ± SD.	25521075

Protocol

References

[4] Hideo Yasuda, et al. Am J Physiol Renal Physiol . 2008 May;294(5):F1050-8.

- Collapse

Solubility (25°C)

In vitro	Water	100 mg/mL (193.85 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Chloroquine diphosphate SDF

Molecular Weight	515.86
Formula	C₁₈H₂₆ClN₃.2H₃O₄P
CAS No.	50-63-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04443270	Not yet recruiting	Drug: Chloroquine phosphate	COVID-19	CMN 20 de Noviembre	July 27 2020	Phase 1
NCT04462367	Recruiting	--	COVID19\|Coronavirus Infection\|Pregnancy Disease\|Severe Acute Respiratory Syndrome	Instituto Materno Infantil Prof. Fernando Figueira	July 1 2020	--
NCT04340544	Terminated	Drug: Hydroxychloroquine\|Drug: Placebo	COVID-19	University Hospital Tuebingen\|Robert Bosch Medical Center\|Universitätsklinikum Hamburg-Eppendorf\|Bernhard Nocht Institute for Tropical Medicine	April 22 2020	Phase 2
NCT02378532	Completed	Drug: Chloroquine\|Radiation: Radiotherapy\|Drug: Temozolomide	Glioblastoma Multiforme	Maastricht Radiation Oncology	August 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

ATM/ATR Signaling Pathway Map

Related ATM/ATR Products

Ceralasertib (AZD6738) ^New

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
KU-55933 (ATM Kinase Inhibitor)

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/K_i of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
ETP-46464

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Choose Your Country or Region

By Signaling Pathways

By product type

Chloroquine diphosphate